Preparation And Characterization Of Magnetic Nanoparticles With Anchored Antibodies For Biomarker Separation From Body Fluids by Demirbağ, Elvan
ISTANBUL TECHNICAL UNIVERSITY  GRADUATE SCHOOL OF SCIENCE 
ENGINEERING AND TECHNOLOGY 
 
 
 
 
 
 
 
 
PREPARATION AND CHARACTERIZATION OF MAGNETIC 
NANOPARTICLES WITH ANCHORED ANTIBODIES FOR BIOMARKER 
SEPARATION FROM BODY FLUIDS 
 
 
 
 
 
 
 
 
 
 
 
M.Sc. THESIS 
 
Elvan DEMĠRBAĞ 
 
 
 
 
 
 
 
Department of Chemical Engineering 
 
Chemical Engineering Programme 
 
 
 
 
 
 
 
 
 
JANUARY 2013 
 
 
  
ISTANBUL TECHNICAL UNIVERSITY  GRADUATE SCHOOL OF SCIENCE 
ENGINEERING AND TECHNOLOGY 
 
 
 
 
 
 
 
 
PREPARATION AND CHARACTERIZATION OF MAGNETIC 
NANOPARTICLES WITH ANCHORED ANTIBODIES FOR BIOMARKER 
SEPARATION FROM BODY FLUIDS 
 
 
 
 
 
 
 
 
 
 
 
M.Sc. THESIS 
 
Elvan DEMĠRBAĞ 
(506081031) 
 
 
 
 
 
 
Department of Chemical Engineering 
 
Chemical Engineering Programme 
 
 
 
Thesis Advisor: Prof. Dr. Özgül Özcan TAġPINAR 
 
 
 
 
 
JANUARY 2013 
 
 
  
  
  
ĠSTANBUL TEKNĠK ÜNĠVERSĠTESĠ  FEN BĠLĠMLERĠ ENSTĠTÜSÜ 
 
 
 
 
 
 
 
 
 
VÜCUT SIVILARINDAN BĠYOGÖSTERGE AYRIMI ĠÇĠN ANTĠKOR 
BAĞLI MAGNETĠK NANOPARTĠKÜL ÜRETĠMĠ VE 
KARAKTERĠZASYONU 
 
 
 
 
 
 
 
 
 
 
 
YÜKSEK LĠSANS TEZĠ 
 
Elvan DEMĠRBAĞ 
(506081031) 
 
 
 
 
 
 
Kimya Mühendisliği Anabilim Dalı 
 
Kimya Mühendisliği Programı 
 
 
 
Tez DanıĢmanı: Prof. Dr. Özgül Özcan TAġPINAR 
 
 
 
 
 
OCAK 2013 
 
 
  
 
 v 
 
Elvan DEMĠRBAĞ, a M.Sc. student of ITU Graduate School of Science, 
Engineering and Technology, student ID 506081031, successfully defended the 
thesis entitled “PREPARATION AND CHARACTERIZATION OF 
MAGNETIC NANOPARTICLES WITH ANCHORED ANTIBODIES FOR 
BIOMARKER SEPARATION FROM BODY FLUIDS”, which she prepared 
after fulfilling the requirements specified in the associated legislations, before the 
jury whose signatures are below. 
 
 
 
Thesis Advisor :    Prof. Dr. Özgül Özcan TAġPINAR .................. 
                                       Ġstanbul Technical University 
 
 
Thesis Co-advisor : Assoc. Prof. Petr Kačer Ph.D ..................
 Institute of Chemical Technology, 
 ICT Prague 
 
Jury Members :    Prof. Dr. Güldem ÜSTÜN .................. 
                                       Ġstanbul Technical University 
 
 
 Doç. Dr. Sibel SARGUT  .................. 
                                       Marmara University 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date of Submission : 17 December 2012 
Date of Defense       : 23 January 2013    
 vi 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 vii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my beloved mother, 
 
 
 
  
 viii 
 
 
  
 ix 
 
FOREWORD  
 
I would like to thank Adéla PANKRÁCOVÁ, M.Sc., for her encouragement, advice 
and support throughout my master of science thesis. I also thank Assoc. Prof. Dr. 
Petr KAČER for his supervision and helpful discussions in magnetic nanoparticles. 
Thanks to everyone I have worked alongside during my M.Sc. in the Department of 
Organic Technology, ICT Prague. In particularly I would like to thank Kateřina 
ŠIMKOVÁ, M.Sc., Kamila SYSLOVÁ, M.Sc., and Yulia Belyaeva for their helps in 
the laboratory. 
I would also like to thank my supervisor in Turkey, Prof. Dr. Özgül Özcan 
TAġPINAR and RNDr. Oldřich BENADA, PhD., from the Academy of Sciences of 
the Czech Republic, for his helps with the transmission electron microscopy (TEM). 
Finally, I would like to thank my beloved mother, Hatice DEMĠRBAĞ for her 
constant support and for always being there. 
 
 
January 2013 Elvan DEMĠRBAĞ 
 (Chemical Engineer)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 x 
 
 
 xi 
 
TABLE OF CONTENTS 
Page 
 
FOREWORD ............................................................................................................. ix 
TABLE OF CONTENTS .......................................................................................... xi 
ABBREVIATIONS ................................................................................................. xiii 
LIST OF TABLES ................................................................................................... xv 
LIST OF FIGURES ............................................................................................... xvii 
SUMMARY ............................................................................................................. xxi 
ÖZET ...................................................................................................................... xxiii 
1. INTRODUCTION .................................................................................................. 1 
2. THEORETICAL PART ........................................................................................ 7 
2.1 Magnetic Nanoparticles ...................................................................................... 7 
2.1.1 Magnetite (Fe3O4) ........................................................................................ 9 
2.2 Synthesis of Magnetic Nanoparticles ............................................................... 10 
2.2.1 Classical synthesis by coprecipitation ....................................................... 10 
2.2.2 Thermal decomposition (High-temperature reactions) .............................. 15 
2.2.3 Hydrothermal reactions ............................................................................. 18 
2.2.4 Microemulsion ........................................................................................... 21 
2.3 Stabilization of Magnetic Nanoparticles .......................................................... 26 
2.4 Functionalization of Magnetic Nanoparticles .................................................. 31 
2.4.1 Polymer coating ......................................................................................... 32 
2.4.1.1 Chitosan .............................................................................................. 32 
2.4.1.2 Dextran ................................................................................................ 36 
2.4.1.3 Other polymers .................................................................................... 38 
2.4.2 Inorganic materials coating ........................................................................ 40 
2.4.2.1 Silica .................................................................................................... 40 
2.4.2.2 Gold ..................................................................................................... 42 
2.4.2.3 Carbon ................................................................................................. 43 
2.5 Characterization of Magnetic Nanoparticles .................................................... 44 
2.5.1 Fourier transform infrared spectroscopy (FT-IR) ...................................... 44 
2.5.2 X-ray powder diffraction (XRD) ............................................................... 46 
2.5.3 Transmission electron microscopy (TEM) ................................................ 47 
2.6 Applications of Magnetic Nanoparticles in Medicine ...................................... 50 
2.6.1 Targeted drug delivery ............................................................................... 50 
2.6.2 Hyperthermia cancer treatment .................................................................. 52 
2.6.3 Magnetic resonance imaging (MRI) .......................................................... 52 
2.6.4 Bioseparation processes ............................................................................. 53 
2.6.4.1 Immunomagnetic separation ............................................................... 56 
3. EXPERIMENTAL PART ................................................................................... 61 
3.1 Substances ........................................................................................................ 61 
3.2 Instruments and Materials ................................................................................ 63 
3.2.1 Fourier transform infrared spectroscopy (FT-IR) ...................................... 63 
3.2.2 X-ray powder diffraction (XRD) ............................................................... 63 
 xii 
 
3.2.3 Transmission electron microscopy (TEM) ................................................ 63 
3.2.4 Liquid chromatography–mass spectrometry (LC-MS) .............................. 64 
3.2.5 Commercially available magnetic particles (Dynabeads M-280 
Tosylactivated) .......................................................................................... 64 
3.2.6 Other apparatus and equipments ................................................................ 65 
3.3 Preparation of Magnetic Fe3O4 Nanoparticles with Oleic Acid ....................... 66 
3.4 Functionalization of Fe3O4 Nanoparticles with Chitosan and  
Glutaraldehyde .................................................................................................. 68 
3.5 Anchoring Antibody onto the Surface of Magnetic Fe3O4–Chitosan 
Nanoparticles .................................................................................................... 70 
3.6 Anchoring Antibody onto the Surface of Dynabeads M-280  
Tosylactivated ................................................................................................... 71 
3.7 Formation of Antibody-Antigen Complexes .................................................... 72 
3.8 Separation of Antigens from Antibody-Antigen Complexes ........................... 73 
3.9 LC-ESI-MS/MS Analysis ................................................................................. 74 
3.10 Collection of Exhaled Breath Condensate ...................................................... 75 
3.11 Preparation of Samples for LC-ESI-MS/MS Analysis – Separation of  
Substances from Exhaled Breath Condensate ................................................ 75 
3.12 Validation of the Method ................................................................................ 75 
3.12.1 Standard preparation and calibration procedure ...................................... 75 
3.12.2 Accuracy and precision ............................................................................ 76 
3.13 Clinical Study ................................................................................................. 76 
4. RESULTS AND DISCUSSION........................................................................... 79 
4.1 Preparation of Immunomagnetic Nanoparticles ............................................... 79 
4.2 Characterization of Magnetic Nanoparticles .................................................... 80 
4.2.1 Fourier transform infrared spectroscopy (FT-IR) ...................................... 80 
4.2.2 X-ray powder diffraction (XRD) ............................................................... 85 
4.2.3 Transmission electron microscopy (TEM) ................................................ 86 
4.3 HPLC-ESI-MS/MS Analysis ............................................................................ 90 
4.4 Calibration Curves and Validation of the Method............................................ 92 
4.5 Repeatability of Immunomagnetic Nanoparticles ............................................ 93 
4.6 Capacity of Immunomagnetic Nanoparticles ................................................... 94 
4.7 Mixing of Immunomagnetic Nanoparticles ...................................................... 95 
4.8 Dynabeads M-280 Tosylactivated with Anchored Antibodies Against  
Cysteinyl Leukotrienes ..................................................................................... 96 
4.9 Clinical Study ................................................................................................... 97 
5. CONCLUSIONS................................................................................................. 101 
REFERENCES ....................................................................................................... 103 
CURRICULUM VITAE ........................................................................................ 117 
 
 
  
 xiii 
 
ABBREVIATIONS 
8-iso PGF2α  : 8-iso Prostaglandin F2α 
8-iso PGF2α-d4  : Deuterium Labelled 8-iso Prostaglandin F2α 
acac  : Acetylacetonate  
AOT  : Dioctyl Sodium Sulfosuccinate 
BSA : Bovine Serum Albumin 
ca. : Circa  
CID : Collision-Induced Dissociation 
Cup : N-nitrosophenylhydroxylamine  
Cys-LTs : Cysteinyl Leukotrienes 
DMSA : 2,3-dimercaptosuccinic Acid  
EBC : Exhaled Breath Condensate 
EIA : Enzyme Immunoassay 
ELISA : Enzyme-Linked Immunosorbent Assay  
ESI : Electro-Spray Ionization 
Fab : Fragment: Antigen Binding 
Fc : Fragment: Crystallizable 
fcc : Face-Centered Cubic 
FTIR : Fourier Transform Infrared Spectroscopy 
GC–MS : Gas Chromatography–Mass Spectrometry 
HPLC : High-Performance Liquid Chromatography 
I : Ionic Strength 
LC–MS : Liquid Chromatography–Mass Spectrometry 
LOD : Limit of Detection 
LOQ : Limit of Quantification 
LTB4 : Leukotriene B4 
LTC4 : Leukotriene C4 
LTC4-d5 : Deuterium Labelled Leukotriene C4 
LTD4 : Leukotriene D4 
LTD4-d5 : Deuterium Labelled Leukotriene D4 
LTE4 : Leukotriene E4 
LTE4-d5 : Deuterium Labelled Leukotriene E4 
LTs : Leukotrienes 
MeOH : Methanol 
MN-8-iso PGF2α  : Magnetic Nanoparticles with Anchored Antibodies Against 
                                 8-iso Prostaglandin F2α 
MN-Cys-LTs : Magnetic Nanoparticles with Anchored Antibodies Against 
                                 Cysteinyl Leukotrienes 
MNPs : Magnetic Nanoparticles  
MRI : Magnetic Resonance Imaging 
OA : Oleic Acid  
PAA : Poly(acrylic acid) 
PAHs : Polycyclic Aromatic Hydrocarbons  
PBS : Phosphate-Buffered Saline  
 xiv 
 
PEG : Poly(ethylene glycol)  
PMAA : Poly(methacrylic acid)  
PVA : Poly(vinyl alcohol)  
PVP : Poly(vinyl pyrrolidone) 
RE : Relative Error 
RIA : Radioimmunoassay  
ROS : Reactive Oxygen Species 
RSD : Relative Standard Deviation  
SD : Standard Deviation 
SPE : Solid-Phase Extraction  
SPIO : Superparamagnetic Iron Oxide 
SPION : Superparamagnetic Iron Oxide Nanoparticles  
SRM : Selected Reaction Monitoring 
TEM : Transmission Electron Microscopy 
THF : Tetrahydrofuran  
TMAOH : Tetramethylammonium Hydroxide 
TRIS : Tris (hydroxymethyl) aminomethane 
XRD : X-ray Powder Diffraction  
 
 
 
 
 xv 
 
LIST OF TABLES 
 
Page 
 
Table 2.1 : Physical and magnetic properties of magnetite ...................................... 10 
Table 2.2 : Characteristic differences between emulsions and microemulsions ....... 22 
Table 3.1 : Chemicals and reagents ........................................................................... 61 
Table 3.2 : Solvents ................................................................................................... 62 
Table 3.3 : Buffers ..................................................................................................... 62 
Table 3.4 : Gases ....................................................................................................... 62 
Table 4.1 : Identification of the functional groups of oleic acid ............................... 81 
Table 4.2 : Identification of the functional groups of chitosan ................................. 82 
Table 4.3 : Identification of the functional groups of glutaraldehyde ....................... 83 
Table 4.4 : Linear regression analysis of calibration curve (n = 10) for  
                   Cys-LTs and 8-iso PGF2α ........................................................................ 92 
Table 4.5 : Validation parameters for Cys-LTs and 8-iso PGF2α in exhaled 
                   breath condensate (n = 5) ........................................................................ 92 
Table 4.6 : Recovery of Cys-LTs and 8-iso PGF2α in the samples ........................... 93 
Table 4.7 : Recovery of Cys-LTs and 8-iso PGF2α in the samples performed by 
                   the immunomagnetic nanoparticles prepared by two different ways ..... 96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xvi 
 
 
  
 xvii 
 
LIST OF FIGURES 
 
Page 
 
Figure 1.1 : Arachidonic acid derivatives – potential biomarkers of bronchial 
                     asthma ..................................................................................................... 3 
Figure 1.2 : The formation of 8-isoprostane ............................................................... 4 
Figure 1.3 : Biological effects of the isoprostanes in the respiratory system ............. 5 
Figure 2.1 : Nanoscale and typical materials whose dimension ranges are 
                     comparable to nanoscale ......................................................................... 7 
Figure 2.2 : Magnetite (Fe3O4) .................................................................................... 9 
Figure 2.3 : Crystal structures of magnetite ................................................................ 9 
Figure 2.4 : High-temperature reaction of iron (III) acetylacetonate ........................ 16 
Figure 2.5 : Synthetic route of water-soluble magnetite nanocrystals ...................... 17 
Figure 2.6 : Chemical reactions involved in the formation of magnetite 
                     nanoparticles ......................................................................................... 17 
Figure 2.7 : Proposed mechanism for the formation of nanoparticles by the 
                     microemulsion approach ....................................................................... 23 
Figure 2.8 : Schematic illustration of particle stabilization via (a) electric 
                     double layer and (b) steric effect ........................................................... 26 
Figure 2.9 : Schematic representation of single layer oleic acid-coated Fe3O4 
                     nanoparticles ......................................................................................... 27 
Figure 2.10 : Schematic representation of bilayer oleic acid-coated Fe3O4 
                       nanoparticles: (a) oleic acid as the secondary layer; (b) oleate 
                       as the secondary layer ......................................................................... 28 
Figure 2.11 : Molecular structure of chitosan ........................................................... 32 
Figure 2.12 : Schematic illustration of chitosan‟s versatility.................................... 33 
Figure 2.13 : Chitosan bonded to Fe3O4 ................................................................... 33 
Figure 2.14 : Schematic representation of the chitosan-glutaraldehyde ................... 34 
Figure 2.15 : Crosslinking process of chitosan treated with glutaraldehyde ............ 34 
Figure 2.16 : The formation process of magnetic Fe3O4–chitosan 
                       nanoparticles with core-shell............................................................... 35 
Figure 2.17 : Schematic representation of dextran ................................................... 36 
Figure 2.18 : Schematic diagram showing the Fe3O4 magnetic nanoparticles 
                       and the dextran coated Fe3O4 magnetic nanoparticles ........................ 37 
Figure 2.19 : Synthesis route for the carboxymethyl dextran coated 
                       magnetic nanoparticles ........................................................................ 38 
Figure 2.20 : FT-IR mechanism ................................................................................ 44 
Figure 2.21 : A simple spectrometer layout .............................................................. 45 
Figure 2.22 : XRD mechanism ................................................................................. 47 
Figure 2.23 : Scattering of X-rays by a crystallite .................................................... 47 
Figure 2.24 : TEM mechanism ................................................................................. 47 
Figure 2.25 : Interaction of a high-energy beam of electrons with a thin 
                       specimen and the resulting secondary signals ..................................... 48 
 xviii 
 
Figure 2.26 : Electron column of a TEM .................................................................. 49 
Figure 2.27 : General scheme of the different applications for magnetic 
                       nanoparticles ........................................................................................ 50 
Figure 2.28 : Examples of magnetic nanoparticles coated with  
                       polysaccharides and decorated with multifunctional receptors ........... 55 
Figure 2.29 : Common chemical moieties for the anchoring of polymers 
                       and functional groups at the surface of magnetic nanoparticles ......... 55                        
Figure 2.30 : The coding and assembly of antibody molecules ................................ 57 
Figure 2.31 : Scheme diagram of immunomagnetic separation of targeted 
                       molecules ............................................................................................. 58 
Figure 3.1 : LC-MS system ....................................................................................... 64 
Figure 3.2 : Dynabeads M-280 Tosylactivated ......................................................... 64 
Figure 3.3 : Ligand coupling protocol for Dynabeads M-280 Tosylactivated .......... 65 
Figure 3.4 : Flowchart of the synthesis of the magnetic Fe3O4 nanoparticles 
                     by co-precipitation................................................................................. 67 
Figure 3.5 : Scheme for the oleic acid modified magnetic Fe3O4 nanoparticles ....... 68 
Figure 3.6 : Flowchart of the preparation of the magnetic Fe3O4-chitosan 
                     nanoparticles .......................................................................................... 69 
Figure 3.7 : Scheme for the chitosan functionalized magnetic Fe3O4  
                     nanoparticles .......................................................................................... 70 
Figure 3.8 : Scheme for the formation of the immunomagnetic nanoparticles ......... 71 
Figure 3.9 : Scheme for formation of antibody-antigen complexes .......................... 72 
Figure 3.10 : Scheme for separation of antigens from antibody-antigen  
                       complexes ............................................................................................ 73 
Figure 3.11 : Scheme for the principle of the immunomagnetic separation  
                       method ................................................................................................. 74 
Figure 4.1 : Summary of the whole process applied in the study ............................. 80 
Figure 4.2 : The infrared spectrum of pure oleic acid ............................................... 81 
Figure 4.3 : The infrared spectrum of chitosan ......................................................... 82 
Figure 4.4 : The infrared spectrum of 50 % of glutaraldehyde solution ................... 83 
Figure 4.5 : The infrared spectrum of oleic acid modified magnetic Fe3O4 
                     nanoparticles .......................................................................................... 84 
Figure 4.6 : The infrared spectrum of magnetic Fe3O4 nanoparticles  
                     stabilized with oleic acid and functionalized with chitosan and 
                     glutaraldehyde ....................................................................................... 85 
Figure 4.7 : Diffractogram of magnetic Fe3O4 nanoparticles ................................... 86 
Figure 4.8 : TEM image of the magnetic Fe3O4-chitosan nanoparticles ................... 87 
Figure 4.9 : TEM image of the magnetic Fe3O4-chitosan nanoparticles and 
                     their sizes in diameter ............................................................................ 88 
Figure 4.10 : TEM image of the antibody anchored magnetic Fe3O4-chitosan 
                       nanoparticles ........................................................................................ 88 
Figure 4.11 : TEM image of the antibody anchored magnetic Fe3O4-chitosan 
                       nanoparticles and their sizes in diameter ............................................. 89 
Figure 4.12 : TEM image of the antibody anchored Dynabeads M-280 
                       Tosylactivated ..................................................................................... 89 
Figure 4.13 : TEM image of the antibody anchored Dynabeads M-280 
                       Tosylactivated and their sizes in diameter .......................................... 90 
Figure 4.14 : MS/MS spectrum of LTC4 ................................................................... 90 
Figure 4.15 : MS/MS spectrum of LTD4 .................................................................. 91 
Figure 4.16 : MS/MS spectrum of LTE4 ................................................................... 91 
 xix 
 
Figure 4.17 : MS/MS spectrum of 8-iso PGF2α ........................................................ 91 
Figure 4.18 : Capacity of immunomagnetic nanoparticles to isolate LTC4,  
                       LTD4 and LTE4 ................................................................................... 94 
Figure 4.19 : Concentration of 8-iso Prostaglandin F2α in EBC in clinical  
                       study .................................................................................................... 97 
Figure 4.20 : Concentration of LTC4 in EBC in clinical study ................................. 98 
Figure 4.21 : Concentration of LTD4 in EBC in clinical study................................. 98 
Figure 4.22 : Concentration of LTE4 in EBC in clinical study ................................. 99 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 xx 
 
  
 xxi 
 
PREPARATION AND CHARACTERIZATION OF MAGNETIC 
NANOPARTICLES WITH ANCHORED ANTIBODIES FOR BIOMARKER 
SEPARATION FROM BODY FLUIDS 
SUMMARY 
In this study, magnetic iron oxide nanoparticles, magnetite (Fe3O4) were synthesized 
through the co-precipitation method of ferrous (Fe
2+
) and ferric (Fe
3+
) aqueous 
solutions by addition of a base (NH4OH) with the mole ratio of Fe
2+
/Fe
3+
 : 1/2. To 
prevent the agglomeration among the particles oleic acid was used, and thus the 
magnetic nanoparticles were stabilized. Then chitosan was added to coat on the 
surface of the Fe3O4 nanoparticles as a polymeric shell. The amino groups on the 
chitosan were cross-linked using glutaraldehyde, and finally the magnetic Fe3O4–
chitosan nanoparticles were obtained. X-ray diffraction pattern indicated that the 
magnetic nanoparticles were pure Fe3O4 with an average diameter of about 5.7 nm. 
TEM results showed that the magnetic Fe3O4–chitosan nanoparticles were quasi-
spherical with a mean diameter of about 8.4 nm. The binding of oleic acid, chitosan 
and glutaraldehyde onto the surface of the magnetic Fe3O4 nanoparticles was 
confirmed by FT-IR.  
After synthesizing the magnetic Fe3O4–chitosan nanoparticles, the immunomagnetic 
nanoparticles were prepared by immobilizing antibodies on the surface of the 
particles by covalent bonding. TEM images demonstrated that the magnetic Fe3O4–
chitosan nanoparticles were successfuly anchored with antibodies. These 
immunomagnetic nanoparticles were used to separate cysteinyl leukotrienes (Cys-
LTs: LTC4, LTD4, and LTE4) and 8-iso Prostaglandin F2α (8-iso PGF2α), which are 
essential biomarkers of asthma and oxidative stress present in exhaled breath 
condensate (EBC), respectively. The principle of separation method was based on 
forming an antibody-antigen (antibody-biomarker) interaction owing to antibodyʼs 
ability to form a specific complex with antigens and isolating targeted molecules by 
applying an external magnetic field.  
The Cys-LTs and 8-iso PGF2α biomarkers, which were treated like antigens in the 
study, were then uncoupled from the resulting antibody-antigen complexes by 
glycine solution through magnetic separation. The amount of separated molecules 
was measured by a highly selective and sensitive detection method: high 
performance liquid chromatography–mass spectrometry (HPLC-MS).  
The analytical procedure was optimized, validated and analytically tested on real 
EBC samples collected from patients diagnosed with two sub-types of bronchial 
asthma (occupational asthma and hard-to-treat asthma) and on the control group of 
healthy subjects. 
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VÜCUT SIVILARINDAN BĠYOGÖSTERGE AYRIMI ĠÇĠN ANTĠKOR 
BAĞLI MAGNETĠK NANOPARTĠKÜL ÜRETĠMĠ VE 
KARAKTERĠZASYONU 
ÖZET 
BronĢiyal astım, tüm dünyada çocukları ve yetiĢkinleri etkileyen halk sağlığı 
sorunlarının baĢında gelmektedir. Astımın dünyada yaklaĢık 300 milyon, ülkemizde 
ise 3.5 milyon kiĢiyi etkilediği düĢünülmektedir. Solunum yolu enflamasyonu ve 
duyarlılığı astım oluĢumunda anahtar rol oynayan temel mekanizmalardır. Bu 
enflamasyon, gece ve sabah erken saatlerde sık görülen öksürük ile beraber 
tekrarlayan hırıltılı solunum, nefessiz kalma ve göğüs sıkıĢmasına sebep olur. Bir 
astım atağı esnasında, solunum yolları kasların büzülmesi sebebiyle aĢırı derecede 
daralır, iç katmanlar ĢiĢer ve mukus üretir. Bu tekrarlayan ataklar, limitli hava 
geçiĢine sebebiyet vererek beklenmeyen ölümlere yol açabilir. BronĢiyal astımın 
tetikleyicileri üç gruba ayrılabilir: 1) genetik yatkınlık ve bağıĢıklık sistemi gibi içsel 
faktörler, 2) alerjenler (polen, küf sporları, toz ya da hayvan tüyü), kapalı ve açık 
mekanlardaki kirleticiler ve tahriĢ edici maddeler (sigara, parfüm, temizlik 
maddeleri, vb.) gibi dıĢ faktörler, 3) fiziksel faktörler (özellikle egzersiz ve soğuk 
hava) ve stres, gastroözofageal reflü hastalığı (GERD) ya da viral ve bakteriyel üst 
solunum yolu enfeksiyonu gibi fizyolojik faktörlerdir. 
Astımın görülme sıklığı, 1995-2010 yılları arasında % 95, yine aynı süreçte 5 yaĢ altı 
çocuklarda ise % 190ʼdan fazla artıĢ göstermiĢtir. 2025 yılına kadar astımlı insan 
sayısının 100 milyon kiĢi daha artacağı tahmin edilmektedir. Bu sebeplerden ötürü, 
doğru ve erken astım teĢhisi ve tedavisi önem kazanmaktadır. Bununla beraber, astım 
hastalığında teĢhis koymak zordur. Günümüzde, astım teĢhisi için kesin bir 
fizyolojik, immünolojik ya da histolojik bir test bulunmamaktadır. Astım teĢhisinde, 
olası aynı semptomları gösteren diğer hastalıkları bertaraf etmek için, genellikle ilk 
olarak akciğer fonksiyonları test edilir. Akciğer fonksiyonlarını ölçmede kullanılan 
testler içerisinde spirometre testi, metakolin ya da histamin zorlama testi ve azot 
oksit testi yer almaktadır. Halihazırda, akciğerlerdeki enflamasyonun ölçümü açık 
akciğer biyopsisi, bronkoalveoler lavaj sıvısının incelenmesi gibi giriĢimsel 
(invasive), indüklenmiĢ sputum metodu gibi yarı-giriĢimsel ya da plazma ve 
idrardaki enflamatuvar göstergelerin ölçümü gibi giriĢimsel olmayan yöntemlere 
dayanmaktadır. 
Biyolojik gösterge (biyogösterge), biyolojik ya da patofizyolojik proseslerin fiziksel 
bir göstergesidir. Biyogöstergeler teĢhis koyma, hastalık evrelendirme ve hastalık 
aktivitesi/ilerleyiĢini görüntüleme gibi çeĢitli amaçlar için kullanılabilir. Özellikle, 
küçük çocuklarda, güvenilir ve giriĢimsel olmayan biyogöstergeler çok önemli 
olabilmektedir. Ayrıca, biyogöstergeler klinik belirti ve semptomlar ya da 
patofizyolojik ölçümler gibi geleneksel hastalık göstergelerine tamamlayıcı bilgiler 
sağlayabilirler. Astımla iliĢkili çok sayıda biyogöstergenin olduğu ve bunların 
solunum yollarındaki karmaĢık enflamasyonu yönettikleri bilinmektedir. Bu 
biyogöstergeler giriĢimsel olmayan ya da yarı-giriĢimsel solunum yolu örnek 
 xxiv 
 
toplama yöntemleriyle elde edilebilir. Alt solunum yollarından, yoğunlaĢtırılmıĢ 
soluk havasının (EBC; exhaled breath condensate) eldesi tamamen giriĢimsiz (non-
invasive) bir örnek toplama tekniğidir. EBC, akciğerler ve solunum yollarının 
durumunu direkt olarak yansıtan bronkoalveoler ekstrasellüler sıvısının belirli bir 
bileĢimini gösterir ve soluk havasının soğutulup yoğunlaĢtırılması ile elde edilir. 
EBC, akciğerlerdeki asit stresin, oksidatif stresin ve enflamasyonun biyogöstergeleri 
olan sisteinil lökotrienler (Cys-LTs: LTC4, LTD4, LTE4), prostaglandinler (8-iso 
Prostaglandin F2α), histamin, adenozin gibi molekülleri içerir. Literatürdeki birçok 
çalıĢmada, EBCʼdeki bu çeĢitli enflamatuvar moleküller, olası astım biyogöstergesi 
olarak araĢtırılmıĢ ve araĢidonik asit türevlerinin (lökotrienler, prostaglandinler) 
astımlı hastaların EBCʼsinde yüksek seviyelerde olduğu gözlemlenmiĢtir. Bu 
nedenle, bu biyogöstergelerin klinik tespit ve ölçümlerinin astım teĢhisinde 
kullanılabileceği düĢünülmüĢtür. 
Lökotrienler, bronĢ mukozasında eozinofil, bazofil ve mast hücresi gibi enflamatuvar 
hücrelerinde sentezlenen ve astım oluĢumunda önemli rolleri olan biyogöstergelerdir. 
Lökotrienlerin bir alt grubu olan sisteinil lökotrienler çok güçlü bronĢ daraltıcı 
maddeler olup astım hastalarının solunum yollarında akut ve kronik yapısal 
bozukluklara neden olabilirler. Son dönemlerde, astım hastalarının bronkoalveoler 
lavaj sıvısı ve balgamlarında yüksek sisteinil lökotrien (LTC4, LTD4, LTE4) 
seviyelerine rastlanmıĢtır.  
8-iso Prostaglandin F2α (8-isoprostan, 8-iso PGF2α), araĢidonik asitin hücre 
yüzeyinde oksijen radikalleri aracılığıyla enzimatik olmayan direkt oksidasyonu ile 
üretilen bir moleküldür. 8-iso Prostaglandin F2α, genellikle oksidatif stresin ve 
antioksidan eksikliğinin önemli bir biyogöstergesi olarak kabul edilir. EBCʼdeki 8-
isoprostan seviyesi, yetiĢkin astım hastalarında artıĢ göstererek hastalığın Ģiddeti ve 
enflamasyonun derecesi hakkında bilgi verir. 
Bu çalıĢmada, kompleks biyolojik matriksler içerisinden astım biyogöstergelerini 
ayırmada kullanılabilecek antikor bağlanmıĢ magnetik demir oksit (Fe3O4: magnetit) 
nanopartikülleri sentezlenmiĢtir. Sentez aĢamasında, molce 1‟e 2 oranında demir (II) 
sülfat ve demir (III) klorür çözeltileri ile amonyum hidroksit (NH4OH) reaksiyona 
sokulmuĢtur. Nanopartiküllerin stabilizasyonu için oleik asit, yüzey 
iĢlevselleĢtirilmesi için kitosan (chitosan) ve çapraz bağlama reaksiyonu için de 
glutaraldehid kullanılmıĢtır. Sentezlenen nanopartiküllerin karakterizasyonu FT-IR, 
XRD ve TEM kullanılarak gerçekleĢtirilmiĢ ve magnetit nanopartiküllerinin kitosan 
ve glutaraldehid ile birlikte baĢarılı bir Ģekilde sentezlendiği saptanmıĢtır.  
Sonraki aĢamada, üretilen bu nanopartiküllere antikor (anti-Cys-LTs ya da anti-8-iso 
PGF2α) eklenmiĢ ve bu Ģekilde iĢlevselleĢtirilen nanopartiküller, Cys-LTs ve 8-iso 
PGF2α moleküllerini bulundukları ortamdan ayırmada kullanılabilecek hâle 
getirilmiĢtir. Nanopartiküllerin antikor ile iĢlevselleĢtirilmiĢ bu formları 
“immünomagnetik nanopartikülˮ, bu partiküllerle gerçekleĢtirilen ayırma iĢlemi de 
“immünomagnetik ayırma yöntemiˮ olarak adlandırılmaktadır.  
ÇalıĢmadaki ayırma prensibi, magnetik nanopartiküllere bağlanmıĢ olan antikorlar ile 
matrikste (EBC) bulunan antijenler (biyogösterge) arasında spesifik bir kompleks 
oluĢturma ve bu kompleksin güçlü bir mıknatıs yardımıyla bulunduğu ortamdan 
ayrılmasına dayanmaktadır. 
OluĢturulan kompleksten biyogöstergelerin ayrılması glisin çözeltisi ve mıknatıs 
yardımıyla gerçekleĢtirilir. EBCʼde bulunan bu biyogöstergeler (Cys-LTs, 8-iso 
PGF2α) çok düĢük konsantrasyonlarda (pg/ml) olduğundan bu moleküllerin miktar 
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tayinlerinde oldukça hassas ve seçici analitik yöntemlere ihtiyaç duyulmaktadır. Bu 
nedenle, bu biyogöstergelerin miktarları yüksek performanslı sıvı kromatografisi ile 
birleĢtirilmiĢ kütle spektrometre cihazı (HPLC-MS) ile saptanmıĢtır.  
Bu çalıĢmada uygulanan analitik prosedür optimize edilmiĢ ve optimum koĢullar 
doğrulanmıĢtır. Daha sonra bu yöntem, astım teĢhisi konmuĢ hastalardan ve kontrol 
grubunu oluĢturan sağlıklı bireylerden alınan gerçek EBC örnekleri üzerinde analitik 
olarak da test edilmiĢtir. 
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1. INTRODUCTION 
Asthma is one of the most common chronic pulmonary diseases with 300 million 
people suffering from it and 250,000 attributed annual deaths. It is characterized by 
reversible airflow obstruction, airway remodeling, and inflammation which is biased 
toward Th2 cytokine production and involves mast cells, eosinophils, lymphocytes, 
macrophages and neutrophils [1,2].  
Bronchial asthma, defined as a chronic inflammatory disorder of the airways, is one 
of the top public health problems globally affecting both children and adults [2]. The 
chronic inflammation is associated with airway hyperresponsiveness that leads to 
recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, 
particularly at night or in the early morning [3]. 
The prevalence of asthma increased by 95 % from 1995 to 2010 and the asthma rates 
in children under the age of five increased by more than 190 % from 1995 to 2010. It 
is estimated that the number of people with asthma will grow by more than 100 
million by 2025. Therefore proper and early diagnostics and treatment is necessary. 
However, the diagnostics can be rather difficult. Currently, there is no precise 
physiological, immunological, or histological test for diagnosing asthma. In order to 
rule out other possible conditions, the lung functions are generally tested first in an 
asthma diagnosis process. Tests to measure the lung functions include spirometry 
test, peak expiratory flow rate test, methacholine or histamine challenge tests and 
nitric oxide test. At present, quantification of inflammation in the lungs is based on 
invasive (open lung biopsy, bronchoalveolar lavage) or semi-invasive methods 
(method of induced sputum) and the measurement of inflammatory markers in 
plasma and urine, which are likely to reflect systemic rather than lung inflammation 
[2].  
A biological marker (biomarker) is a physical sign or laboratory measurement that 
can serve as an indicator of biological or pathophysiological processes or as a 
response to a therapeutic intervention. Biomarkers can be employed for various 
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purposes, including diagnosis, staging and monitoring of disease activity/progression 
or predictors c.q. monitors of a treatment response. Especially in (young) children, 
reliable, non-invasive biomarkers would be valuable. In addition, they can provide 
complementary information to traditional disease markers, such as clinical signs and 
symptoms or pathophysiological measures [4]. 
Presently, there are several biomarkers for asthma that can be obtained by non-
invasive or semi-invasive airway sampling methods. Collection of exhaled breath 
condensate (EBC) is a fully non-invasive sampling technique of the lower airways 
[4]. EBC is a liquid matrix that reﬂects the particular composition of the 
bronchoalveolar extracellular lung liquid, which replicates the conditions proceeding 
directly in the lungs and airways. The substances are contained in the exhaled breath 
in both gaseous and liquid phases (aerosol form). The aerosol particles (non-volatile 
components, including various water-soluble inflammatory markers) and the 
substances present in the gaseous phase (volatile substances such as nitric oxide 
(NO) and carbon dioxide (CO2)) could be condensed by breathing over a condenser, 
which is readily available at specialized clinical facilities. In the obtained liquid, 
typically known as EBC, more than 1000 compounds have been identiﬁed so far, out 
of which a substantial number are considered to represent sensitive biomarkers of 
lung diseases [5,4].  
EBC contains many biomarkers of oxidative and nitrative stress (8-iso Prostaglandin 
F2α, thiobarbituric acid, 3-nitrotyrosine, S-nitrosothiols, etc.) as well as mediators of 
inflammation processes (leukotriene B4: LTB4, cysteinyl leukotrienes (Cys-LTs): 
LTC4, LTD4, LTE4, prostaglandins, histamine, adenosine, interleukins, etc.) [6]. 
Oxidative stress -an imbalance between increased exposure to reactive oxygen 
species (ROS) and antioxidant defences- is thought to contribute to the chronic 
inflammatory process that characterises asthma [7]. It can result in a free radical-
induced damage of cell membranes, proteins or structures with genetic significance 
that are oxidized by ROS. Among them the most prominent are superoxide anion 
(O2
-
) and the hydroxyl radical (OH
-
). Their natural physiological role is to defend the 
organism against a microbial attack. ROS are generated in large concentrations by 
activated granulocytes and can potentially damage any cellular structure. 2-5 % of 
the oxygen amount, typically exchanged during respiration, is used to produce ROS 
in mitochondria. Their activity is under standard conditions well balanced by the 
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antioxidant system. However, this system can be impaired or exhausted by a disease 
or environmental conditions. Uncontrolled ROS activity leads to the organism 
damage by oxidative stress in a target organ (such as lungs), or a systemic damage in 
many organs, caused by atherosclerosis or diabetes. It can harm important bio-
macromolecules as lipids, proteins, enzymes, DNA and thus affect physiological 
processes and/or cause cell death [8]. 
Various inflammatory markers present in EBC have been investigated as possible 
asthma biomarkers and several independent studies have indicated the presence of 
elevated levels of arachidonic acid derivatives (Cys-LTs, LTB4, 8-iso Prostaglandin 
F2α) in EBC of asthma patients. Therefore, measurements of these mediators are 
considered potentially effective in the establishment of asthma diagnosis in a large 
cohort [2]. 
Leukotrienes, a family of lipid mediators derived from arachidonic acid through the 
5-lipoxygenase pathway, are potent constrictors and proinflammatory mediators that 
have been shown to have a role in asthma pathophysiology [9], (Fig. 1.1).  
 
Figure 1.1 : Arachidonic acid derivatives - potential biomarkers of  
bronchial asthma [2]. 
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The cysteinyl leukotrienes (Cys-LTs: LTC4, LTD4, and LTE4) are generated mainly 
by mast cells and eosinophils and are able to contract airway smooth muscle and 
increase mucus secretion and vascular permeability and recruit eosinophils. 
Increased levels of Cys-LTs have been found in bronchoalveolar lavage and induced 
sputum of asthmatic patients. Recently, higher levels of leukotrienes have also been 
found in EBC of asthmatic adults and children [9]. 
8-iso Prostaglandin F2α (=8-isoprostane) is produced in vivo by non-enzymatic direct 
oxidation of arachidonic acid on the cell surface by oxygen radicals (Fig. 1.2). It is 
generally accepted as a significant biomarker of oxidative stress [6] and antioxidant 
deficiency [10].  
 
Figure 1.2 : The formation of 8-isoprostane [10]. 
Concentrations of 8-isoprostane in EBC are increased in adults with stable asthma, 
reflecting the severity of the disease and the degree of inflammation [11]. 8-
isoprostane levels are also a relative indicator of sample integrity for lipid-containing 
samples such as serum, plasma, and whole cell preparations. Plasma from healthy 
volunteers contains modest amounts of 8-isoprostane (40-100 pg/ml) that increase 
with the age of the test subject. Normal human urinary levels range from 10-50 
ng/mmol creatinine, which is an order of magnitude higher than many enzymatically 
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derived eicosanoids [10]. Isoprostanes have different biological effects within the 
respiratory system, suggesting that they may also function as pathophysiological 
mediators of oxidant injury in asthma (Fig. 1.3) [7]. 
 
Figure 1.3 : Biological effects of the isoprostanes in the respiratory system [7]
1
. 
In patients with asthma, airway inflammatory cells including eosinophils, Th2 
lymphocytes, neutrophils and macrophages release increased amounts of reactive 
oxygen species (ROS). These, in turn, cause peroxidation of arachidonic acid in the 
plasma membrane phospholipids with subsequent production of isoprostanes. 
Environmental oxidants can contribute to isoprostane production. Biological effects 
of isoprostanes are compound, species and tissue specific [7]. 
8-iso Prostaglandin F2α as well as the other biomarkers are often detected in EBC at 
levels as low as picograms per milliliter. However, the quantiﬁcation of 
extraordinarily low concentrations of 8-iso Prostaglandin F2α and leukotrienes in 
EBC requires highly sensitive analytical methods. In the past, RIA 
(Radioimmunoassay), EIA (Enzyme Immunoassay), ELISA (Enzyme Linked 
Immunosorbent Assay) and GC–MS (Gas chromatography–mass spectrometry) 
analytical techniques had been used for this task [6,5]. 
                                                     
1
 ROS: reactive oxygen species; AA: arachidonic acid; AHR: airway hyperresponsiveness; NO2:  
nitrogen dioxide; O3: ozone;  SO2: sulfur dioxide. 
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During the last decade, LC-MS/MS has become the technique of choice for the trace 
analysis of various compounds contained in complex biological matrices (plasma, 
urine, cerebrospinal ﬂuid, bronchoalveolar lavage ﬂuid, etc.). It has been successfully 
applied for the detection and quantiﬁcation of EBC markers. In comparison with 
biochemical methods, connecting liquid or gas chromatography to mass spectrometry 
not only offers precise quantitative data but also structural information (qualitative 
information) [6,5]. 
In this study, biomarker (8-iso PGF2α and Cys-LTs) extraction from samples was 
provided by magnetic Fe3O4–chitosan nanoparticles with anchored antibodies. 
Highly specific reactions between antigens (8-iso PGF2α and Cys-LTs) and 
antibodies were formed and the resulting antigen-antibody complexes were separated 
from the solution by using an external magnetic field. For the quantification and 
detection of biomarkers, a highly selective and sensitive method by LC-ESI-MS/MS 
was applied. For its extremely high degree of selectivity, the selected reaction 
monitoring (SRM) mode with collision-induced dissociation (CID) was used. The 
analytical procedure of immunomagnetic separation was tested on real EBC samples 
collected from patients diagnosed with two sub-types of bronchial asthma 
(occupational asthma and hard-to-treat asthma) and on the control group of healthy 
subjects. 
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2. THEORETICAL PART 
2.1 Magnetic Nanoparticles 
Nanotechnology is the understanding and control of matter at the nanoscale, at 
dimensions between approximately 1 and 100 nanometers, where unique phenomena 
enable novel applications. A nanometer is one billionth of a meter [12], (Fig. 2.1).  
 
Figure 2.1 : Nanoscale and typical materials whose dimension ranges  
 are comparable to nanoscale [13]. 
At the nanometer scale, the physical, chemical, and biological properties of materials 
differ in fundamental and valuable ways from the properties of individual atoms and 
molecules or bulk matter [14]. 
Nanoparticles are essential part of our natural environment, modern science, and high 
technology. Magnetic nanoparticles are most common and very promising for 
applications [15]. Magnetic nanoparticles will rotate under an external uniform 
magnetic ﬁeld, and will make translational movements under an external magnetic 
ﬁeld gradient. Therefore, magnetic nanoparticles, or magnetically tagged molecules, 
can be manipulated by applying an external magnetic ﬁeld [16]. 
Among a wide range of the magnetic nanomaterials, nanoparticles of magnetic 
metals (Fe, Co, Ni), simple and complex magnetic oxides (Fe3O4, Fe2O3, FeO, 
FeOOH, Co3O4, NiO), and alloys (Fe-Co, Fe-Ni, Fe-Pt, Co-Pt) may be separated. 
Most magnetic materials used in today‟s technology are either metals or metal 
oxides. Iron is a ferromagnetic material with high magnetic moment density (about 
 8 
 
220 emu/g) and is magnetically soft [15]. Highly magnetic materials such as cobalt 
and nickel are toxic, susceptible to oxidation and hence are of little interest [17].  
Iron oxides are composed of Fe together with O and/or OH. The iron oxides are 
common compounds which are widespread in nature and readily synthezised in the 
laboratory. They are present in almost all of the different compartments of the global 
system: from atmosphere to lithosphere [18]. The iron oxides are also present in 
living organisms (e.g. plants, bacteria, molluscs, birds and humans). Fe(II) 
complexes are the active center of haemoglobin and ferredoxins, and various 
biomineralization processes involve Fe(II) and Fe(III) species for the regulation of 
iron concentration in organism (ferritin) or, in various occurrences, to produce 
different oxides, such as goethite, magnetite, lepidocrocite [19]. 
Iron oxide magnetic nanoparticles tend to be either paramagnetic or 
superparamagnetic, with particles approximately 20 nm being classed as 
superparamagnetic. In most cases superparamagnetic particles (usually Fe2O3 and 
Fe3O4) are of interest for in vivo applications, as they do not retain any magnetism 
after removal of the magnetic ﬁeld. This is important as large domain magnetic and 
paramagnetic materials aggregate after exposure to a magnetic ﬁeld [20]. 
Magnetic particles with suitable surface characteristics have potential applications 
both in vitro and in vivo. In almost all applications, the preparation and surface 
modification of magnetic particles present significant challenges in determining the 
particle size and shape, the size distribution, the surface chemistry and consequently 
the magnetic properties of the particles, all important for application in biomedicine 
[17]. Magnetic nanoparticles can bind to drugs, proteins, enzymes, antibodies, or 
nucleotides and can be directed to an organ, tissue, or tumour using an external 
magnetic ﬁeld or can be heated in alternating magnetic ﬁelds for use in hyperthermia 
[21]. 
Though magnetic nanoparticles with different compositions, sizes and shapes have 
been developed for biomedical applications, the most frequently used magnetic 
materials are two types of iron oxide particles, magnetite (Fe3O4) and maghemite (γ-
Fe2O3) [16]. 
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2.1.1 Magnetite (Fe3O4) 
Magnetite, Fe3O4 (FeO.Fe2O3), is a black, ferrimagnetic mineral containing both Fe
II
 
and Fe
III
 [18], (Fig. 2.2). 
 
Figure 2.2 : Magnetite (Fe3O4) [22]. 
Magnetite is a common magnetic iron oxide that has a cubic inverse spinel structure 
with oxygen forming an fcc closed packing and Fe cations occupying interstitial 
tetrahedral sites and octahedral sites [21], (Fig. 2.3). 
 
Figure 2.3 : Crystal structures of magnetite [23,24]. 
In magnetite (Fe3O4), iron ions are distributed into the octahedral (Oh) and tetrahedral 
(Td) sites of the fcc stacking of oxygen according to ([Fe
3+
]Td[Fe
3+
Fe
2+
]OhO4) [19], 
Formula 1:  
Fe3O4 : [Fe
3+
]Td[Fe
3+ 
Fe
2+
]OhO4 
Formula 1: Structure of magnetite [25]. 
Magnetite is characterized by a fast electron hopping between the iron cations (Fe
2+
 
and Fe
3+
 ions) on the octahedral sublattice [19]. It is frequently non-stoichiometric in 
which case it has a cation deficient Fe
III
 sublattice. In stoichiometric magnetite 
Fe
II
/Fe
III
 = 0.5 [18]. At the stoichiometry Fe
2+
/Fe
3+
 = 0.5, crystallisation of spinel 
 10 
 
phase is quasi-immediate at room temperature [26] and electron transfer between 
Fe
2+
 and Fe
3+ 
ions plays a fundamental role in the process [19]. Table 2.1 shows the 
physical and magnetic properties of magnetite. 
Table 2.1 : Physical and magnetic properties of magnetite [18,23]. 
Property Magnetite 
Molecular formula Fe3O4 
Density (g/cm
3
) 5.18 
Melting point (°C) 1583-1597 
Boiling point (°C) 2623 
Hardness 5.5 
Type of magnetism Ferrimagnetic 
Curie temperature (K) 850 
MS at 300 K (A-m
2
/kg) 92-100 
Standard free 
energy of formation ΔGf° 
(kJ/mol ) 
-1012.6 
Crystallographic system Cubic 
Structural type Inverse spinel 
Space group Fd3m 
Lattice parameter (nm) a = 0.8396 
2.2 Synthesis of Magnetic Nanoparticles 
Numerous chemical methods can be used to synthesize magnetic nanoparticles for 
medical imaging applications: microemulsions, sol-gel syntheses, sonochemical 
reactions, hydrothermal reactions, hydrolysis and thermolysis of precursors, flow 
injection syntheses, and electrospray syntheses. However, the most common method 
for the production of magnetite nanoparticles is the chemical coprecipitation 
technique of iron salts [25]. 
2.2.1 Classical synthesis by coprecipitation 
Precipitation or coprecipitation of cations in aqueous solutions is an easy and cheap 
route of synthesis of metal oxide particles [26]. 
Iron oxides (either Fe3O4 or γ-Fe2O3) can be synthesized through the co-precipitation 
of ferrous (Fe
2+
) and ferric (Fe
3+
) aqueous salt solutions by addition of a base. 
Conventionally, magnetite is prepared by adding a base to an aqueous mixture of 
Fe
2+
 and Fe
3+
 chloride at a 1:2 molar ratio. The precipitated magnetite is black in 
colour. The overall reaction may be written as eq (2.1a) [21] and eq (2.1b) [27]: 
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 Fe
2+
 + 2Fe
3+
 + 8OH
–
 → Fe3O4 + 4H2O (2.1a) 
 FeCl2 + 2FeCl3 + 8NH4OH → Fe3O4 + 8NH4Cl + 4H2O (2.1b) 
According to the thermodynamics of this reaction, complete precipitation of Fe3O4 
should be expected at a pH between 8 and 14, with a stoichiometric ratio of 2:1 
(Fe
3+
/Fe
2+
) in a non-oxidizing oxygen environment [25]. 
Magnetite, Fe3O4 is easily obtained by coprecipitating aqueous Fe
3+
 and Fe
2+
 ions 
with x = 0.66 (x = Fe
3+
/(Fe
2+ 
+ Fe
3+
), the system composition). With x = 0.66, 
corresponding to stoichiometric magnetite, the mean particle size is monitored in the 
range 2–12 nm by the conditions of the medium (precipitation), pH and ionic 
strength (I) imposed by a salt [19]. 
However, magnetite (Fe3O4) is not very stable and is sensitive to oxidation due to the 
high electron mobility in the bulk and transformed into maghemite (γ-Fe2O3) in the 
presence of oxygen [22,25], eq (2.2) [27]: 
 4Fe3O4 + O2 → 6γ-Fe2O3 (2.2) 
Maghemite (γ-Fe2O3) has a structure similar to that of magnetite. It differs from 
magnetite in that all or most Fe is in the trivalent state. Cation vacancies compensate 
for the oxidation of Fe
II
 [18], Formula 2: 
γ-Fe2O3 : 0.75[Fe
3+
]Td[Fe5/3
3+ 
V1/3]OhO4 (where V stands for a cationic vacancy) 
Formula 2: Structure of maghemite [25]. 
In effect, maghemite does not form directly in solution by precipitation of ferric ions, 
but a small proportion of Fe
2+
 (≥ 10 mol %) induces the crystallization of all the iron 
into spinel [19]. It is generally considered to result from the oxidation of 
stoichiometric or nearly stoichiometric magnetites [28]. 
Due to the oxidative instability of Fe
2+
 ions, it is required in some cases to execute 
the co-precipitation of iron ions in inert atmosphere (introduction of nitrogen gas into 
the reaction system). Despite this, several authors report about the successful 
synthesis of magnetite in the presence of oxygen [29]. 
Oxidation in air is not the only way to transform magnetite (Fe3O4) into maghemite 
(γ-Fe2O3) [25]. Jolivet and Tronc have shown that Fe3O4 can be transformed into γ-
Fe2O3 without an oxidizing agent. It likely involves electron trapping in octahedral 
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surface sites [30]. Different mechanisms involving ionic and/or electronic interfacial 
transfers are implicated, depending on the pH of the suspension [26], according to eq 
(2.3) [25]: 
 Fe3O4 + 2H
+
 → γ-Fe2O3 + Fe
2+
 + H2O (2.3) 
In basic medium, the oxidation of magnetite proceeds by oxygen reduction at the 
surface of particles (electron transfer only) and coordination of oxide ions, while in 
acidic medium and anaerobic conditions, surface Fe
2+
 ions are desorbed as hexaaquo 
complexes in solution (electron and ion transfer) according to eq (2.4) [22]: 
 [Fe
3+
]Td[Fe2
2.5+
]Oh O4 + 2 H
+
 → 0.75[Fe3+]Td[Fe5/3
3+ 
V1/3]OhO4 + Fe
2+
 + H2O (2.4) 
In both cases, the oxidation of Fe
2+
 ions is correlated with the migration of cations 
through the lattice framework, creating cationic vacancies in order to keep the charge 
balance [22], explaining the structure of maghemite [25]. 
Fe3O4 might also be oxidized as eq (2.5) [21]: 
 Fe3O4 + 0.25 O2 + 4.5 H2O → 3Fe(OH)3 (2.5) 
Oxidation would critically affect the physical and chemical properties of the 
nanosized magnetic particles. In order to prevent them from possible oxidation in air 
as well as from agglomeration, Fe3O4 nanoparticles produced by reaction (2.1b) are 
usually coated with organic or inorganic molecules during the precipitation process 
[21]. 
Magnetite nanoparticles, prepared by coprecipitation of Fe
2+
 and Fe
3+
 with NH4OH, 
can be stabilized with silica to form well-dispersed magnetic silica nanospheres. The 
addition of chelating organic anions (carboxylate or α hydroxy carboxylate ions, such 
as citric, gluconic, or oleic acid) or polymer surface complexing agents (dextran, 
carboxydextran, starch, or polyvinyl alcohol) during the formation of magnetite can 
help to control the size of the nanoparticles [25]. 
The major advantage of precipitation reactions is that large quantities of particles can 
be synthesised. However, it is difﬁcult to tailor the particle size as only kinetic 
factors are available to control growth [31].  
Particles prepared by co-precipitation unfortunately tend to be rather polydisperse. It 
is well known that a short burst of nucleation and subsequent slow controlled growth 
is crucial to produce monodisperse particles [32]. 
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Controlling these processes is therefore the key in the production of monodisperse 
iron oxide magnetic nanoparticles [32]. The properties of ﬁnely divided magnetic 
materials closely depend on the size of the particles and their state of dispersion and 
aggregation. It is therefore very important to carefully control the synthesis of 
particles and their surface state. In these conditions, well-deﬁned materials regarding 
the crystal structure, the mean particle size, the size distribution, the morphology and 
the state of dispersion appear very difficult to obtain, because it is difficult to control 
the reactions [26]. 
Size, shape and composition of magnetic nanoparticles are dependent on; 
 type of salts used (e.g. chlorides, sulphates, nitrates, etc.),  
 ratio of Fe
2+
 and Fe
3+
,  
 pH value, 
 ionic strength of the reaction system [29]. 
The mean size is strongly dependent on the acidity and the ionic strength of the 
precipitation medium, and clearly decreases with increasing pH and I [26]. 
Another disadvantage of these bulk solution synthesis is that the pH value of the 
reaction mixture has to be adjusted in both the synthesis and puriﬁcation steps. As a 
result, the production of signiﬁcant quantities of narrowly dispersed, nanometer sized 
magnetic particles remains a signiﬁcant challenge through these methods [21]. 
A wide variety of factors can be adjusted in the synthesis of iron oxide nanoparticles 
to control size, magnetic characteristics, or surface properties. A number of studies 
have dealt with the inﬂuence of these different factors [25]. 
Khalafalla and Reimers (1980) described a method to prepare dilution-stable aqueous 
magnetic fluids. The preparation method involved precipitation of mixed ferrous and 
ferric hydroxides followed by peptization of the colloidal magnetite particles with 
dodecanoic acid. In the method, FeCI2.4H2O, FeCl3.6H2O and ammonium hydroxide 
(NH4OH) were used. The mixture represented an initial molar ratio of Fe(III) to 
Fe(II) of 3:2. Dodecylamine was then added to the precipitate, and the mixture 
heated at 90°C for 4 minutes while stirring. The resulting magnetic fluid had a 
saturation magnetization of 200 gauss [33]. 
The first controlled preparation of superparamagnetic iron oxide particles using 
alkaline precipitation of FeCl3 and FeCl2 was performed by Massart (1981). The 
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Massart process described the coprecipitation without molecules for stabilization 
[25]. In this process, an aqueous mixture of ferric chloride and ferrous chloride were 
added to ammonia solution. The gelatinous precipitate was isolated from the solution 
by centrifugation or magnetic decantation without washing with water. There were 
two ways of treating this precipitate: alkaline sol and acidic sol. In these alkaline or 
acidic magnetic sols, iron concentrations higher than one molar could easily be 
obtained. A very peculiar observance was that a sol could be obtained only if the 
Fe(III)/Fe(II) ratio was larger than two (as in Fe3O4). It was observed that the size 
decreases when the pH and/or the initial ratio Fe(III)/Fe(II) increase [34]. 
In another study of E. Tronc et al. (1982), aqueous solutions of ferrous and ferric 
chloride were added to NH3 in excess, at fixed pH and temperature. Various samples 
were obtained by varying only the Fe
2+
/Fe
3+
 relative concentration at the initial step 
of the reaction. Electron micrographs confirmed that the particles were roughly 
spherical. All samples, as long as the Fe
2+
 initial concentration was not too low, 
exhibited X-ray diffraction patterns characteristic of the spinel structure. The cell 
parameters were in the range 8.375 - 8.36 Å [35]. 
After pioneer work being reported by Massart and Khalafalla, coprecipitation was 
widely studied in preparing magnetite nanoparticles for its extraordinary advantages, 
such as gram-scale production and facility. In fact, almost all the magnetite 
nanoparticles used in clinical research nowadays are prepared by classical 
coprecipitation, because their surface can be easily modified to be hydrophilic, which 
is suitable for biomedical applications [36]. 
Jolivet et al. reported an investigation of magnetite as a function of the initial Fe(II) 
level (0.10 < x ≤ 0.50). Aqueous mixtures of FeCl3 and FeCl2 in various proportions 
were added to an NH3 solution with vigorous stirring at room temperature. At any x 
value, all stable products exhibited the structure of (oxidized) magnetite [37].  
Babes et al. have studied the inﬂuence of different parameters such as media 
composition, iron media, injection ﬂuxes, Fe and tetramethylammonium hydroxide 
(TMAOH) concentrations, temperature, and oxygen on size, magnetic and magnetic 
resonance relaxometric properties, and colloidal stability of particles. They have 
determined the relative importance of these parameters as well as the optimal 
conditions for obtaining uncoated stable particles with an average size of 5 nm and 
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interesting relaxivities. Among the parameters, TMAOH concentration (0.25-2 M) 
and synthesis temperature (20–50°C) showed little or no influence in the 
experimental setup. Only the difference of the sizes of the particles prepared at 20 
and 65°C was statistically significant, with lower relaxivities and sizes with 
increasing temperature [38]. 
The particle size or shape can be varied easily by controlling the pH and the ionic 
strength in the medium of synthesis [39]. The higher the pH and ionic strength, the 
smaller the particle size and size distribution width will be, because these parameters 
determine the chemical composition of the crystal surface and consequently the 
electrostatic surface charge of the particles [25]. 
Qiu et al. investigated that the size of the magnetic particles was dependent on both 
temperature and the ionic strength of the iron ion solutions. Magnetic nanoparticles 
with average diameter in the range of 6.4–8.3 nm have been synthesized by a 
chemical co-precipitation of Fe(II) and Fe(III) salts in NH4OH solution. The 
magnetic particles formed at higher temperature or lower ionic strength were slightly 
larger than those formed at lower temperature or higher ionic strength respectively. 
In spite of the different reaction conditions, all the resultant nanoparticles were 
nearly spherical and had a similar crystalline structure. At 300 K, such prepared 
nanoparticles were superparamagnetic [40]. 
Some other factors have an inﬂuence on the size of the nanoparticles. For example, 
an increase of the mixing rate tends to decrease the particle size. The different studies 
also show that the formation of magnetite particles decreases with an increase in the 
temperature. Bubbling nitrogen gas through the solution not only protects against 
critical oxidation of the magnetite but also reduces the particle size when compared 
to methods without oxygen removal [25]. 
2.2.2 Thermal decomposition (High-temperature reactions) 
Nanoparticles with a high level of monodispersity and size control can be obtained 
by high-temperature decomposition of iron organic precursors, such as Fe(Cup)3, 
Fe(CO)5, or Fe(acac)3 (acac = acetylacetonate) using organic solvents and surfactants 
[25]. Fatty acids, oleic acid, and hexadecylamine are often used as surfactants [32].  
The size and morphology of the nanoparticles can be controlled by controlling the 
reaction times and the temperature but also the concentration and ratios of the 
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reactants, nature of the solvent, precursors, complexing strength, and addition of 
seeds. The adsorption of a surfactant onto the surface of the iron nanoparticle 
stabilizes the colloid solution [25]. 
K. Woo et al. prepared hydrophobic magnetite nanoparticles with a narrow size 
distribution by thermal decomposition of Fe(CO)5 in octyl ether solution of oleic acid 
and by consecutive aeration. The nanoparticles were converted into magnetite 
core/silica shell (magnetite@silica) structured particles with hydrophilic and 
processible aminopropyl groups on their surfaces [41]. 
Sun et al. reported a convenient organic phase process for making monodisperse 
Fe3O4 nanoparticles through the reaction of Fe(acac)3 and a long-chain alcohol [42]. 
They demonstrated that high-temperature (265°C) reaction of iron (III) 
acetylacetonate, Fe(acac)3, in phenyl ether in the presence of alcohol, oleic acid, and 
oleylamine could be used to make size-controlled monodisperse magnetite 
nanoparticles (Fig. 2.4) [43]. 
 
Figure 2.4 : High-temperature reaction of iron (III) acetylacetonate [43]. 
According to the Figure 2.4, the 4-nm Fe3O4 nanoparticles were made as follows: 
Fe(acac)3 (2 mmol) was mixed in phenyl ether (20 mL) with 1,2-hexadecanediol (10 
mmol), oleic acid (6 mmol), and oleylamine (6 mmol) under nitrogen and was heated 
to reflux for 30 min. After cooled to room temperature, the dark-brown mixture was 
treated with ethanol under air, and a dark-brown material was precipitated from the 
solution. The product was dissolved in hexane in the presence of oleic acid and 
oleylamine and reprecipitated with ethanol to give 4 nm Fe3O4 nanoparticles [43]. 
As magnetic nanoparticles synthesized in an organic environment often have better 
crystallinity and monodispersity than those synthesized in an aqueous environment, a 
method of transferring organically synthesized particles to aqueous conditions is 
clearly desirable [44]. Therefore, it is very important to further develop the thermal 
decomposition method to directly synthesize water-soluble magnetic nanoparticles 
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by using strong polar molecules to modify the magnetic nanoparticles [45]. Li et al. 
reported a one-pot reaction to achieve water-soluble iron oxide nanocrystals by 
thermal decomposition of Fe(acac)3 in 2-pyrrolidone (Fig. 2.5) and results of surface 
coordination of the magnetic nanocrystals obtained. In the one-pot reaction, 2-
pyrrolidone was chosen as solvent and stabilizer because it has strong polarity, a high 
boiling point, and coordination capacity with transition metal ions [45]. 
 
Figure 2.5 : Synthetic route of water-soluble magnetite nanocrystals [45]. 
Li et al. have also presented a simple route to synthesize water-soluble magnetite 
nanocrystals by refluxing inexpensive FeCl3.6H2O as iron source instead of costly 
[Fe(acac)3]. In addition, the mechanism leading to Fe3O4 in 2-pyrrolidone was 
discussed. Differently sized (average particle sizes were 4, 12, and 60 nm) and 
shaped (from spherical to cubic with increasing reﬂux time) magnetite nanocrystals 
could be obtained simply by varying the reaction time. In accordance with the 
results, a possible mechanism leading to magnetite nanocrystals is proposed in Fig. 
2.6 [46].  
 
Figure 2.6 : Chemical reactions involved in the formation of  
magnetite nanoparticles [46]. 
In Fig. 2.6, the equation (2) is a process involving dissolution of FeCl3.6H2O in 2-
pyrrolidone and azetidine-catalyzed hydrolysis of FeCl3. In fact, the thermal 
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decomposition of 2-pyrrolidone is rather complex. Therefore, Fig. 2.6 does not depict 
all decomposition reactions that take place. Only those related to the formation of 
magnetite nanocrystals are shown [46]. 
Jun et al. reported the synthesis of magnetic Fe3O4 nanocrystals through thermal 
decomposition of Fe(acac)3 in a hot organic solvent. The size of these nanocrystals 
was controlled from 4 to 6, 9, and 12 nm with high monodispersity. It was necessary 
to develop a multifunctional ligand system that allows one to transfer the 
nanocrystals from the organic to the aqueous phase, a simple but highly effective 2,3-
dimercaptosuccinic acid (DMSA) ligand was exchanged onto the nanocrystal 
surface. Obtained Fe3O4 nanocrystals with the DMSA ligand were fairly stable in 
water and phosphate-buffered saline (PBS) without any aggregation [47]. 
2.2.3 Hydrothermal reactions 
Hydrothermal reactions are aqueous reactions carried out using autoclaves or high 
pressure reactors where the pressure can be over 2000 psi at temperatures above 
200°C. Water acts as a reactant at these supercritical conditions, accelerating the 
kinetics of the hydrolysis reactions. At increased temperatures, the solubility of most 
ionic species increases and, with the lower viscosity of water, exhibits greater 
mobility. The increased mobility allows Ostwald ripening to continue at a faster rate 
increasing the uniformity of the precipitates [31]. 
Hydrothermal method has many advantages: the use of organic reagents are waived, 
relatively cost-effective, high yield of products and excellent particle crystallinity 
with controllable size and good morphology of particles can be easily obtained. In 
addition, no post-heat treatment is required for the produced nanoparticles which 
makes this method highly desirable as heat treatment might result in particle 
agglomeration [48]. 
Hydrothermal synthesis of Fe3O4 nanoparticles in organic solvent-free system is 
useful because of simplicity of the process and relatively low environmental impact. 
In normal hydrothermal synthesis technique, a mixed aqueous solution of ferrous and 
ferric ions is used as the starting solution, and precipitates of ferrous hydroxide 
(Fe(OH)2) and goethite (α-FeOOH) are formed as the precursor via coprecipitation in 
an alkaline solution [49]. 
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There are two main routes for the formation of ferrites via hydrothermal conditions: 
hydrolysis and oxidation, and neutralisation of mixed metal hydroxides. Some lesser 
routes involve the hydrothermal treatment of mixed metal oxides, or the use of other 
solvents such as ethylene glycol at supercritical conditions. Hydrolysis and oxidation 
reactions are very similar to neutralisation reactions where the former uses ferrous 
salts as opposed to ferric salts in the latter [31]. 
During the hydrothermal process of preparing magnetite, several factors such as 
temperature, pH values, and the amount of iron powder should be considered [50]. 
Size and morphological control in hydrothermal reactions is achieved by controlling 
time and temperature. The reaction conditions of precursor material and pH have an 
impact on phase purity of the nanoparticles [31]. Indeed, it was observed that the 
particle size of Fe3O4 powders increased with a prolonged reaction time and that 
higher water content resulted in the precipitation of larger Fe3O4 particles [25]. 
Under hydrothermal conditions a broad range of nanostructured materials can be 
formed. Li et al. reported a generalized hydrothermal method for synthesizing a 
variety of different nanocrystals by a liquid–solid–solution reaction. The system 
consists of metal linoleate (solid), an ethanol–linoleic acid liquid phase, and a water–
ethanol solution at different reaction temperatures under hydrothermal conditions 
[32]. 
Konishi et al. hydrothermally prepared Fe3O4 powders from Fe(III) carboxylate using 
alcohol as the solvent (this method is known as the solvothermal method) [51]. In the 
absence of water, the heat treatment of the iron carboxylate solution at 245°C (0.45 
MPa) led to the formation of magnetite alone. The resulting magnetite was 
crystalline particles with size ca. 0.1 µm and was free from contamination by the 
organic starting material [52]. 
D. Chen and R. Xu hydrothermally synthesized Fe3O4 particles from iron(II) 2-
methoxyethoxides (Fe(OMOE)2), using 2-methoxyethanol (MOE)–water mixed 
solvent as the medium. Their experiments showed that the borderline synthesis 
conditions were a reaction temperature of about 140°C, a reaction time from 42 to 64 
h, and a volume ratio of MOE/H2O in the range 1.4 –2.0 [51]. 
Si et al. have reported a facile method to produce monodisperse magnetite 
nanoparticles via the reaction between Fe powder and FeCl3.6H2O. The solvethermal 
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reaction was carried out at 180°C in n-hexane in the presence of oleic acid and 
laurylamine. Fe3O4 nanocrystals with sizes of 5.2, 7.9, 9.8, 11.7, and 12.7 nm were 
synthesized through the sealed reaction in 3, 6, 12, 18, and 24 h, respectively. These 
Fe3O4 nanocrystals were soluble in oil phases such as hexane. Comparing the 
experiments of aqueous syntheses through different processes, the system of organic-
surfactant in this solvothermal process has important roles in slowing the nucleation 
rate and preventing the particle aggregation [53]. Though this method has been 
proved to be effective in increasing the crystallinity, the magnetite nanoparticles 
obtained exhibit poor water solubility, which limits their application in biomedical 
ﬁelds [54]. 
S. Xuan et al. reported the preparation of water-soluble magnetite nanoparticles by a 
hydrothermal method. In this work, hydrated ferric salt was employed as a single 
iron precursor and ascorbic acid as a reducing agent to synthesize superparamagnetic 
Fe3O4 nanocrystals, which capped with C6H6O6 (the oxidation state of ascorbic acid) 
[54]. 
A possible formation mechanism of the magnetite nanocrystals was suggested as 
follows [54]:  
 2Fe
3+
 + 3CO3
2-
 + 6H2O → 2Fe(OH)3 + 3H2CO3 (2.6) 
 2Fe(OH)3 + C6H8O6 → 2Fe(OH)2 + C6H6O6 + 2H2O (2.7) 
 2Fe(OH)3 + Fe(OH)2 → Fe3O4 + 4H2O (2.8) 
C.Y. Haw et al. synthesized Fe3O4 nanoparticles using hydrothermal method. The 
black precipitate of Fe3O4 nanoparticles is then transferred into an autoclave and 
heated to 200°C for 1 h. Earlier studies suggest that if hydrothermal temperature is 
greater than 160°C, it would possibly result in bigger particles size. Lower 
hydrothermal temperatures of 120 or 80°C have a tendency to produce smaller size 
distribution of Fe3O4 nanoparticles. Besides, the duration of heating process may also 
play important role in the production of Fe3O4 nanoparticles. Mao et al. synthesized 
Fe3O4 nanoparticles at 180°C for 24 h and their results indicate that the Fe3O4 
nanoparticles produced are of well-deﬁned crystal shape and bigger due to the 
recrystallization. Contrastingly, in the study of C.Y. Haw et al., the obtained Fe3O4 
nanoparticles are of spherical shape with average diameters of 17.12 nm [48]. 
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N. Mizutani et al. carried out the hydrothermal synthesis of Fe3O4 nanoparticles by 
using the starting solution containing lactate and sulfate ions at various 
concentrations in order to control the particle size. Under the experimental conditions 
in this work, the median particle size could be varied from 9.5 to 38.6 nm. Therefore, 
it has been demonstrated that the particle size is controlled by means of the 
coexistence effects of lactate and sulfate ions. The size control can be carried out 
precisely by adjusting their concentration in the starting solution properly as the 
operating factor [49]. 
Y. Qian et al. prepared homogeneous ultrafine magnetite particles by means of a 
hydrothermal procedure in the temperature range of 130°-150°C, starting from a 
solution of iron chloride (FeCI3.6H2O) and iron powder, using urea as precipitant. No 
iron powder remained in the products, and the yield of magnetite was above 95 % 
[50]. 
A mechanism of the formation of magnetite in the hydrothermal process can be 
proposed as follows [50]: 
 Fe + 2H2O → Fe(OH)2 + H2 (2.9) 
 Fe
3+
 + 3NH3.H2O → Fe(OH)3 + 3NH4
+ 
(2.10) 
 Fe
3+
 + 3NH3.H2O → Fe(OH)3 + 3NH4
+ 
(2.11) 
 Fe(OH)2 + 2Fe(OH)3 → Fe3O4 + 4H2O (2.12) 
R. Fan et al. have synthesized nanocrystalline magnetite successfully by 
hydrothermal reaction of aqueous ferrous sulfate (FeSO4), sodium hydroxide and 
sodium thiosulfate (Na2S2O3). They were homogenous with an average size of 50 nm 
and the yield of the magnetite was above 90 %. The total reaction was related as 
follows [55]: 
 3Fe
2+
 + 2S2O3
2- 
+ O2(aq) + 4OH
-
 → Fe3O4(s) + S4O6
2- 
+ 2H2O (2.13) 
2.2.4 Microemulsion 
A microemulsion is a thermodynamically stable dispersion of two relatively 
immiscible liquids stabilized by surfactant molecules [56]. Surfactant (also known as 
stabilizer or emulsifier) is an amphiphilic molecule that possesses both polar and 
non-polar moieties, consisting of hydrophilic (likes water) and hydrophobic (fears 
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water) components [57]. Microemulsions should not be regarded as emulsions with 
very small droplet size; micro- and macroemulsions are fundamentally different 
(Table 2.2) [58].  
Table 2.2 : Characteristic differences between emulsions and microemulsions [58]. 
Emulsion Microemulsion 
Unstable, will eventually separate Thermodynamically stable 
Relatively large droplets (1-10 µm) Small aggregates  (  10 nm) 
Relatively static system Highly dynamic system 
Moderately large internal surface, 
moderate amount of surfactant needed 
High internal surface, high 
amount of surfactant needed 
Small oil/water curvature 
The oil/water interfacial film 
can be highly curved 
Depending on relative concentrations, surfactant molecules self-assemble into a 
variety of structures in the solvent mixture, such as micelles, bilayers and vesicles. 
Most commonly used structures in nanoparticle synthesis are micelles, either as 
reverse (water-in-oil) or normal (oil-in-water) form. In both cases, the dispersed 
phase consists of monodispersed droplets in the size range of 2–100 nm. This 
dispersed phase provides a conﬁned environment for synthesizing nanoscale particles 
[56]. 
In water-in-oil microemulsions, the aqueous phase is dispersed as microdroplets 
(typically 1–50 nm in diameter) surrounded by a monolayer of surfactant molecules 
in the continuous hydrocarbon phase. The size of the reverse micelle is determined 
by the molar ratio of water to surfactant. By mixing two identical water-in-oil 
microemulsions containing the desired reactants, the microdroplets will continuously 
collide, coalesce, and break again, and finally a precipitate forms in the micelles. By 
the addition of solvent, such as acetone or ethanol, to the microemulsions, the 
precipitate can be extracted by filtering or centrifuging the mixture. In this sense, a 
microemulsion can be used as a nanoreactor for the formation of nanoparticles [32]. 
A common way to achieve a uniform particle size is to carry out the synthesis in the 
interior of small microemulsion liquid droplets. For example, metallic nanoparticles 
were produced in microemulsions by combining adequate amounts of organic 
solvent, water and surfactant, a precursor of metal ions and reducing agents [57]. The 
most widely used approach is shown in Fig. 2.7. This involves the preparation of two 
separate microemulsions, incorporating the different reactants. Upon mixing, 
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nucleation occurs on the micelle edges as the water inside them becomes 
supersaturated with reactants. Growth then occurs around this nucleation point, with 
the arrival of more reactant fed via intermicellar exchange [59]. 
 
Figure 2.7 : Proposed mechanism for the formation of nanoparticles  
by the microemulsion approach [59]. 
The water-in-oil emulsions are currently being used to synthesize superparamagnetic 
iron oxide nanoparticles with a narrow size range and uniform physical properties 
because of the ability to control the size and shape of the nanoparticles. The main 
advantage of using this type of emulsion system is that the size of the nanoparticles 
can be controlled by modulating the size of the aqueous droplets core [25]. 
Gupta and Wells reported an approach to prepare magnetic polymeric nanoparticles 
with magnetic core and polymeric shell using inverse microemulsion polymerization 
process. Poly(ethyleneglycol) (PEG) modified superparamagnetic iron oxide 
nanoparticles with specific shape and size have been prepared inside the aqueous 
cores of AOT/n-Hexane reverse micelles. The inverse microemulsion polymerization 
of a polymerizable derivative of PEG and a cross-linking agent resulted in a stable 
hydrophilic polymeric shell of the nanoparticles. The results showed that the 
particles are spherical in shape with core–shell structure. The average size of the 
PEG-modified nanoparticles was found to be around 40–50 nm with narrow size 
distribution [60]. 
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The inexpensive large-scale synthesis of uniform and highly crystalline magnetite 
nanoparticles using reverse micelles as nanoreactors under reflux conditions has been 
recently described by Y. Lee et al. (2005). The key feature of this synthetic 
procedure was the maintenance of the micelle structure during the formation of the 
nanoparticles at high reaction temperature. In the study, the particle size could be 
controlled from 2 nm to 10 nm by varying the relative concentrations of the iron 
salts, surfactant, and solvent [61]. 
J. Vidal-Vidal et al. presented a one-pot microemulsion method to produce both 
coated and uncoated magnetic nanoparticles. A water-in-oil microemulsion 
(cyclohexane/Brij-97/aqueous phase) was chosen because it is stable at moderated 
temperatures and uses a non-ionic surfactant. The nanoparticles were formed by the 
coprecipitation reaction of ferrous and ferric salts with two organic bases, 
cyclohexylamine and oleylamine, into a water-in-oil microemulsion. The results 
showed that when oleylamine was used as precipitant agent, a stable colloidal 
dispersion of maghemite nanoparticles coated with oleylamine was obtained. In 
contrast, cyclohexylamine did not avoid the aggregation of the particles during the 
synthesis. It was shown that the oleylamine adsorbed at particle surface could be 
easily replaced by oleic acid, due to its strong chemisorption when carboxilate 
bonded to Fe
3+
 at the particle surface. The obtained particles coated with oleylamine 
(or oleic acid) showed a narrow size distribution of 3.5 ± 0.6 nm; were spherical 
shaped and well crystallized; had high saturation magnetization; and were strong 
protected by a monolayer coating [62]. 
J. Zhi et al. have suggested a new method of in situ preparation of magnetic 
chitosan/Fe3O4 composite nanoparticles in microreactors of tiny water pools of 
water-in-oil microemulsion. Tiny water pools of water-in-oil microemulsion are ideal 
nano-sized microreactors for the preparation of nanoparticles, such as GeO2, CdS and 
BaSO4. Chitosan solution was prepared by dissolving chitosan powder in 
hydrochloric acid. Cyclohexane, n-hexanol, hydrochloric acid (HCl) solution 
containing chitosan and ferrous salt solutions were mixed at the volume ratio of 
55:30:8:8. The microemulsion was formed by adding Triton X-100 (surfactant) into 
the mixture. Through adding the basic solution of NaOH into the microemulsion 
containing chitosan and ferrous salt, the magnetic Fe3O4 and chitosan nanoparticles 
were precipitated from the system. The magnetic iron oxide nanoparticles were 
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surrounded by the chitosan nanoparticles. The size of the magnetic chitosan 
nanoparticles ranged from 10 nm to 80 nm [63]. 
Another method to synthesise nanoparticles is from a single microemulsion. One of 
the desired reactants is solubilised inside reverse micelles, and a second reactant 
(often a reductant) added directly to the system. This is a common way to produce 
metal nanoparticles [59]. 
A novel approach to prepare magnetic polymeric nanoparticles by synthesis of the 
magnetite core and polymeric shell in a single inverse microemulsion was reported 
by Dresco et al. The particle size was varied in the range 80-320 nm by changing of 
the monomer concentration and water/surfactant ratio. The technique of synthesizing 
a core and a shell in a single microemulsion has improved the particle structure and 
size distribution [64]. 
Microemulsion-based syntheses are typically carried out at low temperatures. They 
are easy to be scaled up to an industrial level, but they suffer from some 
disadvantages [56]:  
 extensively agglomerated nanoparticles are often generated [61]. 
 particles are sometimes less crystalline and more polydispersed because of the 
slow nucleation rate at low reaction temperatures [56].  
 it is an expensive method due to the large amounts of surfactant (as much as 20–
30%) and solvent added to the system [57,32]. 
 the yield of nanoparticles is often very low compared to other methods, such as 
thermal decomposition and co-precipitation. In other words, a large amount of 
solvent is used to synthesize a very small amount of nanoparticles [61,32]. 
 although many types of magnetic nanoparticles have been synthesized in a 
controlled manner using the microemulsion method, the particle size and shapes 
usually vary over a relative wide range, and the working window for the 
synthesis in microemulsions is usually quite narrow [32]. 
 the surfactant ensuring colloidal stability is adsorbed on the surface of the 
nanoparticles, thereby decreasing their usability [57]. 
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2.3 Stabilization of Magnetic Nanoparticles 
Magnetic nanoparticles contain hundreds to thousands of single atoms/ions and have 
extremely large surface energy and magnetic interactions [65]. In the absence of any 
surface coating, magnetic iron oxide particles have hydrophobic surfaces with a large 
surface area to volume ratio. Due to hydrophobic interactions between the particles, 
these particles agglomerate and form large clusters, resulting in increased particle 
size [21]. Dependent upon the pH of the solution, the surface of the magnetite will be 
positive or negative [25]. The principal cause of aggregation is the short-range 
forces-van der Waals attraction between the two particles. To counteract these 
attractive interactions and promote stability, equally short-range repulsive forces are 
required. They are enforced either by electrostatic repulsion between the particles or 
by coating the particles with organic long-chain molecules [66], as indicated in Fig. 
2.8 [65]. The stabilization of nanoparticles seems to result from thermodynamics 
rather than kinetics [67]. 
 
Figure 2.8 : Schematic illustration of particle stabilization via (a) electric  
double layer and (b) steric effect [65]. 
Electrostatic stabilization (see Fig. 2.8a) is based on the Coulombic repulsion 
between the particles caused by the electrical double layer formed by ions adsorbed 
at the particle surface (e.g. sodium citrate) and the corresponding counterions. This is 
exemplified by the gold sols prepared by the reduction of [AuCl4]
–
 with sodium 
citrate. Steric stabilization (see Fig. 2.8b) is achieved by the coordination of sterically 
demanding organic molecules that act as protective shields on the metallic surface. In 
this way, nanometallic cores are separated from each other and agglomeration is 
prevented. The main classes of protective groups selected from the literature are: 
polymers and block copolymers; P, N, and S donors (e.g. phosphanes, amines, 
thioethers); solvents such as THF, THF/MeOH, and propylene carbonate; long-chain 
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alcohols; surfactants; and organometallics [68]. Oleic acid (C18H34O2) is a commonly 
used surfactant to modify the magnetic nanoparticles synthesized by the traditional 
co-precipitation method compared to other surfactants [69]. 
The surfactants can form the single layer or bilayer coated structure on the surface of 
nanoparticles. When Fe3O4 nanoparticles were coated by single layer oleic acid, the 
two oxygen atoms of COO in oleic acid provided two coordination positions to form 
the chemical interaction with Fe atom. The studies showed that the primary layer in 
the bilayer coated structure was chemically absorbed on the surface of nanoparticles 
(Fig. 2.9), and the secondary layer was physically absorbed on the primary layer 
through the interpenetration of the tails of the primary and secondary surfactants at 
their interface (Fig. 2.10) [70]. 
 
Figure 2.9 : Schematic representation of single layer oleic  
acid-coated Fe3O4 nanoparticles [70]. 
The long hydrocarbon chains of the surfactants are responsible for the 
hydrophobicity. These long aliphatic chains also cause the nanoparticles to be 
immiscible in the aqueous solution, and the biological applications of these 
nanoparticles are greatly restricted because of their poor solubility in aqueous 
solution [71]. Bilayer oleic acid-coated Fe3O4 nanoparticles can be applied in more 
areas than single layer oleic acid-coated ones because they can be well dispersed not 
only in nonpolar carrier liquids but also in polar carrier liquids, while the single layer 
oleic acid-coated ones can be dispersed only in nonpolar carrier liquids [70]. 
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Figure 2.10 : Schematic representation of bilayer oleic acid-coated  
Fe3O4 nanoparticles: (a) oleic acid as the secondary  
layer; (b) oleate as the secondary layer [70]. 
Both in the single layer and bilayer oleic acid-coated Fe3O4 are contributed to be the 
strong chemical bond formed between the carboxylic acid and the amorphous iron 
oxide nanoparticles. However, too much oleic acid will make nanoparticles reunite 
into spherical, and too little oleic acid is also not sufficient to coat all of the 
nanoparticles completely, therefore it is critical to coat appropriate amount of oleic 
acid. Though K. Yang et al. have found the FTIR bound at 1710 cm
-1
 was the 
characteristic band for the secondary layer in bilayer oleic acid-coated Fe3O4, but 
there is still no suitable determination method to judge the optimum amount of oleic 
acid coated in Fe3O4 nanoparticles [69]. 
While some research has focused on the synthesis of magnetic particles stabilized by 
surfactant bilayers, little is known about the stabilization mechanisms underlying 
such systems in terms of the interfacial interactions that might exist. Indeed, the 
concept of surfactant bilayer stabilization has not yet progressed beyond being a 
reasonable hypothesis. Quantitative experimental characterizations of such systems 
are still rare and the results are inconsistent with each other [72].  
Ferroﬂuids or magnetic ﬂuids are stable colloidal homogeneous suspensions of 
magnetic nanoparticles (around 10 nm in diameter) in an appropriate carrier (aqueous 
or non-aqueous) liquid. D. Maity and D.C. Agrawal have prepared iron oxide 
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nanoparticles using Fe
3+
/Fe
2+ 
= 1.5/1, stabilized in oil (dodecane and kerosene) and 
water media. The particles have been suspended in non-aqueous and aqueous media 
by coating the particles with a single layer and a bilayer of oleic acid, respectively. 
The particle size of the powder was found to be much reduced when a surfactant 
(oleic acid) was used during the preparation. Particles coated with a single layer of 
surfactant could be stabilized in kerosene and dodecane while the bilayer coating was 
necessary to obtain the water-based ferroﬂuids [73]. 
Yan Wei et al. developed an efficient modification method using sodium citrate and 
oleic acid for the synthesis of Fe3O4 magnetic nanoparticles (MNPs) with narrow 
size distribution and excellent dispersion in fluids. Fe3O4 MNPs were synthesized by 
a co-precipitation method at different temperatures, and modified with sodium citrate 
and oleic acid respectively. Phase composition and microstructure analysis indicated 
that the sodium citrate and oleic acid have been successfully grafted onto the surface 
of Fe3O4 MNPs by chemical bond. Sodium citrate and oleic acid modified Fe3O4 
MNPs showed excellent dispersion capibility in aqueous or inaqueous solution [74]. 
Sahoo et al. reported the surface derivatization of magnetite (Fe3O4) by oleic acid 
(OA), lauric acid (LA), dodecylphosphonic acid (DDP), hexadecylphosphonic acid 
(HDP), and dihexadecyl phosphate (DHDP) and compared the properties of 
carboxylic acid coated particles to colloidal nanoparticles coated with phosphonate 
or phosphate ligands. Coated magnetite nanoparticles with a 6-8 nm average 
diameter were prepared. Transmission electron microscopy analyses of the 
aggregation of the coated particles suggested that carboxylate surfactants provided 
the particles with better isolation and dispersibility as compared with phosphonate 
surfactants. Magnetic nanoparticles coated with oleic acid were easily dispersed in a 
nonpolar solvent like hexane, while the ones coated with lauric acid were not [75]. 
Another way to prepare stable magnetite particles is to coat magnetite particles with 
a polymeric material. Various techniques are used for preparing polymer 
encapsulated iron oxide particles. Some of those techniques are based on, ﬁrst, 
precipitating iron oxide particles, and then coating the precipitated particles with 
polymers [76]. 
Polymers containing functional groups, such as carboxylic acids, phosphates, and 
sulfates, can bind to the surface of magnetite. Suitable polymers for coating include 
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poly(pyrrole), poly(aniline), poly(alkylcyanoacrylates), poly(methylidene malonate), 
and polyesters, such as poly(lactic acid), poly (glycolic acid), poly(ε-caprolactone), 
and their copolymers [32]. 
H. Zhang et al. have reported a method to prepare poly(methacrylic acid) (PMAA)-
capped Fe3O4 nanoparticles by coprecipitation with PMAA in aqueous solution. 
Transmission electron micrographs and selected area electron diffraction pattern 
revealed the Fe3O4 nanoparticles to be approximately 8 nm in diameter with a cubic 
phase structure [77]. 
J. Lee et al. presented ultraﬁne magnetite particles of average diameter 4-7 nm 
prepared by precipitation in a poly (vinylalcohol) (PVA) aqueous solution. PVA is a 
hydrophilic polymer and serves as a protective agent to stabilize colloidal dispersions 
of magnetite. The results showed that the crystallinity of the particles decreased with 
increasing PVA concentration, while the morphology and particle sizes remained 
almost unchanged. The dispersion of the magnetite particles prepared at 1 wt % PVA 
was particularly stable [78]. 
Various methods have been reported for the preparation of stable dispersions of iron 
oxide in organic solvents (organosols), including hexane and decane. However, for 
these organosols, the biological applications are greatly restricted because of their 
poor solubility in aqueous solutions. For biomedical applications, it is essential to 
develop nanoscale magnetite with a narrow size distribution and surface coating with 
biocompatibility materials, i.e., nonimmunogenic, nonantigenic, and protein-resistant 
[66]. 
A.L. Andrade et al. have reported a direct reduction–precipitation method to prepare 
ferroﬂuids containing chemically stabilized nanoparticles of magnetite (Fe3O4) with 
tetramethylammonium hydroxide (TMAOH). To ensure that the Fe3O4 nanoparticles 
were monodispersed, their surfaces were modiﬁed by adsorbing TMAOH. TMAOH 
was used as protective agent to decrease particle aggregation, due interparticle 
interaction; the electrostatic repulsion effect was mainly caused by charges of the 
tetramethylammonium cations adsorbed on the particle surface, in the water medium. 
The post-synthesis autoclave-heating promoted the decrease of the mean particle size 
and TMAOH tended to satisfactorily keep particles well dispersed, making the 
resulting primary material suitable for many technological applications [79]. 
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Santra et al. reported a water-in-oil microemulsion method for the preparation of 
silica-coated iron oxide nanoparticles. Three different nonionic surfactants (Triton X-
100, Igepal CO-520, and Brij-97) have been used for the preparation of 
microemulsions, and their effects on the particle size, crystallinity, and the magnetic 
properties have been studied. All the particles showed magnetic behavior close to 
that of superparamagnetic materials. By use of this method, magnetic nanoparticles 
as small as 1-2 nm and of very uniform size (percentage standard deviation was less 
than 10 %) have been synthesized [80]. 
2.4 Functionalization of Magnetic Nanoparticles 
The aim of surface functionalization of magnetic composite particles, such as 
polymer-coated magnetic particles and silica-coated magnetic particles, is to 
introduce some functional groups on the surface for immobilizing various 
biomolecules and biological ligands [17]. 
Functionalization of magnetic nanoparticles (MNPs) with amino group, silica, 
polymer, various surfactans or other organic compounds is usually provided in order 
to achieve better physical and chemical properties. Moreover, the core/shell structure 
of MNPs have the advantages of good dispersion, high stability against oxidation. 
Furthermore, lots of functional groups from polymers on the surface can be used for 
further functionalization to get various properties [81]. 
Apart from enabling the selective binding of different bioactive molecules, the 
functionalized nanoparticles must exhibit appropriate magnetic properties; they have 
to be non-toxic, hydrophilic, and biocompatible, and they have to remain stable in 
aqueous colloidal suspensions. One of the preferred functional groups for bonding 
different bioactive molecules to nanoparticles is the amino group [82]. 
Several groups of coating materials are used to modify MNP surface chemistry: 
a) organic polymers, such as dextran, chitosan, polyethylene glycol, 
polysorbate, polyaniline, 
b) organic surfactants, such as sodium oleate and dodecylamine, 
c) inorganic metals, such as gold, 
d) inorganic oxides, such as silica and carbon, 
e) bioactive molecules and structures (liposomes, ligands/receptors) [83].  
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2.4.1 Polymer coating 
Coating organic polymers on the surface of MNPs endows the particles some 
important properties that the bare particles lack. Polymer coating could enhance the 
compatibility between nanoparticles and aqueous medium, prevent particles from 
oxidation, reduce toxicity, extend storage life and facilitate transport, etc. Polymers 
for coating can be classiﬁed into natural and synthetic substances. Natural polymers 
include dextran, chitosan, gelatin, etc. Synthetic polymers include poly 
(ethyleneglycol) (PEG), poly (vinylpyrrolidone) (PVP), poly (vinyl alcohol) (PVA) 
and polyacrylic acid (PAA), etc. [84]. 
2.4.1.1 Chitosan 
Chitosan, poly(1→4)-2-amino-2-deoxy-ᴅ-glucan, is a poly(amino saccharide) with 
many signiﬁcant biological (biodegradable, biocompatible, bioactive) and chemical 
properties (polycationic, hydrogel, reactive groups such as OH and NH2) [85], (Fig. 
2.11). Chitosan is the alkaline deacetylated product of chitin [63]. 
 
Figure 2.11 : Molecular structure of chitosan [87]. 
Chitin, poly(1→4)-2-acetamido-2-deoxy-β-ᴅ-glucan is a naturally occurring polymer 
extracted from crustacean shells, such as prawns, crabs, krill, insects and shrimps. It 
is the second most abundant biopolymer next to cellulose. By partially deacetylating 
the acetamido groups in its side chain with a strong alkaline solution, chitin is 
converted to chitosan, which is non-toxic, hydrophilic and anti-bacterial [86]. 
Chitosan has both hydroxyl and amine groups that can be chemically modiﬁed [88]. 
The amino groups on the chitosan can also be used for further functionalization with 
speciﬁc components, such as various drugs, speciﬁc binding sites, or other functional 
groups. Chitosan is a suitable kind of polymer to be used to modify the Fe3O4 
nanoparticles [89].  
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The presence of the amino groups indicates that pH substantially alters the charged 
state and properties of chitosan. At low pH, these amines get protonated and become 
positively charged and that makes chitosan a water-soluble cationic polyelectrolyte. 
On the other hand, as the pH increases above 6, chitosan‟s amines become 
deprotonated and the polymer loses its charge and becomes insoluble (Fig. 2.12) 
[90]. 
 
Figure 2.12 : Schematic illustration of chitosan‟s versatility [90]. 
Several methods have been used to modify raw chitosan ﬂake either physical or 
chemical modiﬁcations [88]. Sungwook Hong et al. synthesized iron oxide (Fe3O4) 
nanoparticles coated with biocompatible chitosan for use as an MRI (magnetic 
resonance imaging) contrast agent. The average diameter of the coated particles was 
67 nm. As can be seen from the Fig. 2.13, the amino group (NH2) of chitosan is 
bonded to the particle. However, the hydroxyl group (-OH) of chitosan remains 
unbonded. Consequently, the coated particles are slightly positively charged. Due to 
the Coulomb repulsion between these positively charged particles, the aqueous 
solution of the coated particles remains in a state of colloidal suspension when no 
organic solvent or surfactant is used [91]. 
 
Figure 2.13 : Chitosan bonded to Fe3O4 [91]. 
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Chitosan is often crosslinked, using a variety of agents, including glutaraldehyde and 
sodium tripolyphosphate. The glutaraldehyde forms a bridge between the NH3
+
 
groups of the chitosan [92], (Fig. 2.14).  
 
Figure 2.14 : Schematic representation of the chitosan-glutaraldehyde [93]. 
The aldehyde groups of the glutaraldehyde form covalent imine bonds with the 
amino groups of chitosan, due to the resonance established with adjacent double 
ethylenic bonds via a Schiff reaction (Fig. 2.15) [94]. 
 
Figure 2.15 : Crosslinking process of chitosan treated with glutaraldehyde [94]. 
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Gui-yin Li et al. synthesized magnetic Fe3O4–chitosan nanoparticles by the covalent 
binding of chitosan onto the surface of magnetic Fe3O4 nanoparticles. Firstly, Fe3O4 
were prepared by hydrothermal method using H2O2 as an oxidizer, then chitosan and 
Fe3O4 aqueous slurry were mixed by appropriate proportion with reverse-phase 
suspension cross-linking method to form the magnetic nanoparticles with amine 
group. The formation process of magnetic Fe3O4–chitosan nanoparticles was shown 
in Fig. 2.16. TEM results showed that Fe3O4 particles and Fe3O4–chitosan 
nanocomposites were regular sphere with a mean diameter of 23 nm and 25 nm, 
respectively [95]. 
 
Figure 2.16 : The formation process of magnetic Fe3O4–chitosan  
                                       nanoparticles with core-shell [95]. 
J. Qu et al. prepared Fe3O4–chitosan nanoparticles with core-shell structure by 
crosslinking method. Oleic acid modiﬁed Fe3O4 nanoparticles were ﬁrstly prepared 
by co-precipitation then chitosan was added to coat on the surface of the Fe3O4 
nanoparticles by physical absorption. The Fe3O4–chitosan nanoparticles were 
obtained by crosslinking the amino groups on the chitosan using glutaraldehyde. The 
particle size of the composite nanoparticles was 10.5 nm and the size distribution 
was narrow. The Fe3O4–chitosan nanoparticles exhibited high saturation 
magnetization (30.7 emu/g) and superparamagnetic property [89]. 
Zhao et al. synthesized Fe3O4–chitosan magnetic composite nanoparticles with a 
core–shell structure with a diameter of 30–50 nm by two steps via a suspension 
cross-linking method. The potential of Fe3O4–chitosan composite nanoparticles was 
evaluated for localized hyperthermia treatment of cancers and it was found that the 
Fe3O4–chitosan composite nanoparticles would be good thermoseeds for localized 
hyperthermia cancer therapy [96]. 
E.H. Kim et al. developed microspheres composed of superparamagnetic iron oxide 
(SPIO; Fe3O4; magnetite) nanoparticles and chitosan as a novel MRI-detectable 
embolic material. They prepared spherical SPIO nanoparticles about 15 nm in radius 
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by sonochemistry, and embedded them in chitosan to synthesize a ferroﬂuid. To 
make an embolic material, the synthesized ferroﬂuid was sprayed on the surface of 
an alkali solution so that the ferroﬂuid in microsphere form was dispersed in the 
solution. Considering their uniform size and shape, the SPIO particles were suitable 
to prepare ferroﬂuids for medical applications. In this study, the SPIO-chitosan 
microspheres showed a strong enhancement of MR image contrast similar to the 
ferroﬂuid in vitro [97]. 
B. Feng et al. demonstrated a novel approach to synthesis monodisperse magnetite 
nanoparticles (3–5 nm in diameter) by using a chitosan–polyacrylic acid (CS–PAA) 
template. The results revealed that the Fe3O4 nanoparticles were 3–5 nm in size with 
excellent dispersibility. The particles exhibited superparamagnetic property with 
saturation magnetizations of 40.7 emu/g. In addition, the current samples were 
chosen to perform on MRI, the results indicated that the nanoparticles prepared by 
current synthetic approach could be potential used as T2-type contrast agents in MR 
imaging [98]. 
2.4.1.2 Dextran 
Dextran is a polymer (C6H10O5)n, of anhydroglucose having mainly alpha-D(1-6) 
linkages with some unusual 1,3 glucosidic linkages at branching points [99], (Fig. 
2.17). It is a natural polysaccharide that ﬁnds wide use in the pharmaceutical ﬁeld. It 
is water soluble, inert in biological systems and does not affect cell viability [100]. 
 
Figure 2.17 : Schematic representation of dextran [101]. 
Dextran is a good stabilizer for nanoscale magnetite owing to its excellent 
biocompatibility and water-solubility, and has been utilized in both laboratory 
products and some commercial MNPs [102]. 
H. Bai et al. reported a new method of synthesizing a kind of dextran coated Fe3O4 
magnetic nanoparticles draw solute to technologically integrate the good solubility of 
dextran, which can generate sufﬁcient osmotic pressure for brackish water 
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desalination, and the strong magnetism of Fe3O4 magnetic nanoparticles, which is 
beneﬁcial for the easy separation of the draw solutes by an external magnet. They 
concluded that the dextran coated Fe3O4 magnetic nanoparticles used as draw solutes 
would bring beneﬁts to the clean water production via promoting the forward 
osmosis system in an environmental friendly and energy saving manner. A schematic 
diagram to show the difference between pure Fe3O4 magnetic nanoparticles and the 
dextran coated Fe3O4 magnetic nanoparticles is shown in Fig. 2.18 [103]. 
J. Hradil et al. prepared dextran-modiﬁed iron oxide nanoparticles by precipitation of 
Fe(II) and Fe(III) salts with ammonium hydroxide by two methods. Iron oxide was 
precipitated either in the presence of dextran solution, or the dextran solution was 
added after precipitation. In the second method, the iron oxide particle size and size 
distribution could be controlled depending on the concentration of dextran in the 
solution. The dextran/iron oxide ratio 0–0.16 used in precipitation of iron salts could 
be recommended for synthesis of nanoparticles suitable for biomedical applications, 
as the colloid did not contain excess dextran and did not coagulate [104]. 
 
Figure 2.18 : Schematic diagram showing the Fe3O4 magnetic nanoparticles  
and the dextran coated Fe3O4 magnetic nanoparticles [103]. 
When magnetite/dextran nanocomposite was prepared by a one-step method, dextran 
was linked with MNPs through van der Waals force and hydrogen bond. In this case, 
when magnetic ﬂuid was injected into veins, the magnetic ﬂuid will be diluted, 
leading to the precipitation of the magnetic nanoparticles. In order to resolve the 
problem, a two-step method was proposed to bond dextran onto the surface of MNPs 
through chemical linkage [84]. 
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R.Y. Hong et al. presented a one-step method for preparing biocompatible ferroﬂuid 
based on dextran-coated Fe3O4 magnetic nanoparticles. The biocompatible ferroﬂuid 
was intravenously injected into rabbits, bio-distribution of ferroﬂuid in organs and 
blood was investigated. The MRI of the rabbit liver, marrow and lymph were 
analyzed after the ferroﬂuid was injected. The results showed that the tumor could 
easily be identiﬁed, which indicated a potential application of the as-prepared 
magnetic nanoparticles in functional molecular imaging for biomedical research and 
clinical diagnosis [105]. 
G. Liu et al. synthesized superparamagnetic nanoparticles functionalized with 
carboxymethyl dextran (CM-dextran) by a two-step method, as shown in Fig. 2.19. 
First, the magnetic nanoparticles (MNPs) coated with dextran were prepared by co-
precipitation of Fe
2+
 and Fe
3+
 ions. Then, dextran on the surface of MNPs reacted 
with monochloroacetic acid (MCA) in alkaline condition. The MRI experiment 
indicated that the CM-dextran MNPs could potentially be used as MRI contrast 
agents for magnetic resonance molecular imaging [106]. 
 
Figure 2.19 : Synthesis route for the carboxymethyl dextran coated  
magnetic nanoparticles [106]. 
2.4.1.3 Other polymers 
Polyethylene glycol (PEG) is a polymer widely used for its hydrophilicity and low 
antigenicity. In addition to steric stabilization of MNPs, PEG prevents their plasma 
opsonization and uptake by macrophages, increasing MNP circulation in vivo. PEG-
coated MNPs are efﬁciently internalized by cells via ﬂuid-phase endocytosis and 
through amphiphilic afﬁnity to lipid bilayers on plasma membranes. These qualities, 
however, increase their potential to overload cells with iron and become toxic [83]. 
Gupta and Curtis prepared poly(ethyleneglycol) (PEG) modified superparamagnetic 
iron oxide nanoparticles and studied their influence on human fibroblasts. The aim of 
the study was to modify the surfaces of the magnetic nanoparticles with PEG to 
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improve the biocompatibility of the nanoparticles by resisting protein adsorption and 
increasing their intracellular uptake. The results showed that the PEG coated 
nanoparticles did not affect the cell adhesion behaviour and morphology and their 
internalisation into endosomes offer the opportunity to label a variety of cells with 
high efficiency [107]. 
Polyvinyl alcohol (PVA) is a synthetic, water soluble polymer with excellent ﬁlm 
forming, emulsifying, and adhesive properties [108]. It is a biocompatible polymer 
that is also attractive due to its high functionality and hydrogel-like properties, and is 
widely used as a dispersing agent for preventing particle coagulation and 
contributing to their stability and monodispersity [109]. 
A. Petri-Fink et al. developed functionalized superparamagnetic iron oxide 
nanoparticles (SPION) for interaction with human cancer cells. SPION (mean 
diameter 9 nm) were coated with various ratios to iron oxide of either polyvinyl 
alcohol (PVA), carboxylate-functionalized PVA, thiol-functionalized PVA and 
amino-functionalized PVA (amino-PVA). The interaction with cells and cytotoxicity 
of the SPION preparations were determined using human melanoma cells. From the 
four functionalized SPION preparations, only the amino-PVA SPION demonstrated 
the capacity to interact with, and were not cytotoxic to, human melanoma cells [110]. 
Polyvinylpyrrolidone (PVP), a polymer widely used in pharmaceutical formulations, 
forms covalent adducts with drugs containing nucleophilic functional groups [111]. 
In synthetic conditions, PVP molecules not only prevent the aggregation of the Fe3O4 
nanoparticles, but also restrict their size by utilizing the interaction between the 
carbon atoms in carbonyl groups and the Fe atoms on the Fe3O4 nanoparticles. Y. 
Zhang et al. synthesized PVP-coated ultra-small Fe3O4 nanoparticles as MRI contrast 
agent. The as-prepared Fe3O4 nanoparticles with diameter from 6.5 to 1.9 nm were 
homogeneous and well dispersed. In vivo results for MRI and magnetic targeting 
showed that the PVP coated Fe3O4 particles could be concentrated at the target area 
and obviously exhibited negative contrast enhancement for the whole body [112]. 
Xu et al. reported a simpliﬁed method for synthesis of polyacrylic acid-bound iron 
oxide magnetic nanoparticles (Fe3O4@PAA NPs) on the basis of the amine-
functionalized magnetite nanoparticles which were synthesized by a facile one-pot 
hydrothermal method without templates. The Fe3O4@PAA NPs had been utilized as 
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environment friendly adsorbent for the removal of rhodamine 6G (R6G) (as a model 
basic dye pollutant from aqueous solution) added to the aqueous sample from the 
Yellow River due to the high efﬁciency and fast adsorption process, as well as simple 
and convenient magnetic separation [113]. 
2.4.2 Inorganic materials coating 
Iron oxide nanoparticles can be coated with silica, gold or gadolinium(III). These 
coatings not only provide stability to the nanoparticles in solution but also help in 
binding various biological ligands to the nanoparticle surface. These nanoparticles 
have an inner iron oxide core with an outer metallic shell of inorganic materials [25]. 
2.4.2.1 Silica  
Silica is known to be biocompatible but not biodegradable. Amorphous silica coating 
on magnetite NPs was ﬁrst reported by Philipse et al. with a sol–gel approach. As 
silica is hydrophilic in nature, the silica-coated core–shell particles were reported to 
be well dispersed in aqueous suspensions. The silica-coated SPIONs can be 
negatively charged above the isoelectric point of silica (pH∼2); hence, they have 
been used for separation of biomolecules through electrostatic interactions. In 
addition, silica has hydroxyl groups (silanol group: Si-OH) useful for the attachment 
of further functionalities through covalent bonding with organosilanes [114]. Such a 
capability opens the door to the design and synthesis of magnetic carriers that can be 
used to deliver drugs to targeted organs via highly speciﬁc recognition (e.g. 
antibody–antigen interaction) [115]. 
Organosilanes are bifunctional molecules with the general formula X-(CH2)n-
SiRn(OR′)3-n, where X represents the headgroup functionality, (CH2)n a flexible 
spacer, and Si(OR)n the anchor groups by which (after hydrolysis of the alkoxy 
group) they can attach to free Si-OH surface groups. Alkoxysilanes with a variety of 
X functionalities are commercially available, amino groups being one of the most 
frequently used for biological applications. These can be employed in silanization of 
surfaces via a range of procedures including organic phase, aqueous phase, and 
chemical vapor deposition of the silane. Silanization in solution is the most common 
approach since it does not restrict the use of volatile compounds and is not required 
to be performed under vacuum [116]. 
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Silica coated iron oxide nanoparticles are commercially available as contrast agents 
for MRI (Lumirem®). The protocol to obtain silica coated nanoparticles involves the 
synthesis of the magnetic nanoparticles and a series of reactions to grow the coating 
layer based on the Stöber method. Finally the functionalization of the coating is 
undertaken [117]. In Stöber process, silica is formed in situ through the hydrolysis 
and condensation of a sol-gel precursor [118]. 
J.H. Chang et al. developed molecularly assembled silica coated magnetic 
nanoparticles for protein separation such as bovine serum albumin (BSA) and 
lysozyme (LSZ) at different pH conditions. After the process of silica coating on the 
magnetic nanoparticle, the monolayers of organosilanes were grafted on the silica 
coated magnetic nanoparticles to enforce the covalent bonding and to capture the 
target proteins as the anchored probes. Work on using these amino functionalized 
silica coated magnetic nanoparticles for protein puriﬁcation indicated that they have 
many advantages such as easy preparation, low cost, easy handling and rapid 
puriﬁcation [119].  
K. Ashtari et al. prepared silica-encapsulated magnetic nanoparticles (MNPs) via 
microemulsion method. MNPs with no observed cytotoxic activity against human 
lung carcinoma cell and brine shrimp lethality were used as suitable support for 
glucose oxidase (GOD) immobilization. The results demonstrated potential 
biocompatible applicability of the silica-encapsulated MNPs for biomedical 
applications [120]. 
Kang et al. described a simple and convenient process for highly efﬁcient and direct 
DNA separation with functionalized silica-coated magnetic nanoparticles. The 
efﬁciency of the DNA separation was explored via the function of the amino-group 
numbers, particle size, the amount of the nanoparticles used, and the concentration of 
NaCl salt. The adsorption efficiency of aminofunctionalized nanoparticles was the 4-
5 times (80-100 %) higher compared to silica-coated nanoparticles only (10-20 %) 
[121]. 
Yu et al. reported a synthesis of silica encapsulated magnetic nanosize particles (4–
11 nm) as a magnetic separable carrier based on a simple microemulsion technique. 
The silica coating surface is shown to isolate and protect the magnetic core from 
reactive environment where a range of conditions for magnetic separation can be 
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made possible. Thus, it is demonstrated that the relatively smaller size coated 
magnetic nanoparticle can carry bulky protein, the bovine serum albumin (BSA) on 
the silica overlayer surface [122]. 
2.4.2.2 Gold 
Precious metals, such as gold, have been used to protect iron oxide cores against 
oxidation, as they form highly stable particles of low reactivity. Nanogold is known 
for its superior optical properties, biocompatibility and outstanding capacity for 
functionalization. These properties make gold a particularly attractive surface 
chemistry for MNPs. One limitation is that gold coating can weaken magnetic 
properties of iron oxide MNPs and is considered difﬁcult to achieve due to the 
dissimilar nature of the two surfaces. When achieved, gold-coated MNPs are stable 
under neutral and acidic conditions. Engineering a continuous gold shell over an 
MNP core is a challenge, but it can provide an extremely effective barrier against 
oxidizing agents [83]. 
Goon et al. reported a facile method of synthesizing 50-150 nm magnetite-gold 
composites via the use of a biocompatible polyelectrolyte, polyethyleneimine (PEI), 
for the dual function of attaching gold seeds and preventing the formation of large 
aggregates. They demonstrated the importance of having a saturated surface of gold 
seeds in obtaining gold shells and also showed that this shell imparts resistance to 
chemical attack [123]. 
Kim et al. prepared monodispersed gold coated superparamagnetic iron oxide 
nanoparticles (Au@SPION) in water-in-oil reverse microemulsion. The reverse 
micelle microreactor was prepared with CTAB (cetyltrimethyl–ammonium bromide), 
octane, and varying the water to surfactant ratio and molar ratio between cosurfactant 
and surfactant. Morphological analysis by TEM showed that Au@SPION, with 
average sizes 9 nm and narrow size distribution [124]. 
Salgueirino-Maceira et al. reported a method for the development of bifunctional 
magnetic and optically tunable nanoparticles with a structural design involving a 
magnetic iron oxide core (Fe3O4/γ-Fe2O3) surrounded by a thick silica shell and 
further covered with an outer shell of gold. These gold-coated magnetic silica 
spheres take advantage of the strong resonance absorption they show in the visible 
and near-infrared (NIR) range and can be controlled by using an external magnetic 
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field, which makes them very promising in biomedical applications. They can be 
controlled through the blood stream using an external magnetic field, therefore 
favoring their selective accumulation at the targeted pathologic tissue [125]. 
2.4.2.3 Carbon 
One way to protect metal nanoparticles is to encapsulate the particles with a 
chemically  stable species, such as graphite. Carbon is one of the best solutions for 
encapsulation as it is light, cheap and highly stable under extreme chemical and 
physical environments. The carbon coatings immunize the nanoparticles against 
environmental degradation and therefore retain their intrinsic nanocrystalline 
properties. Furthermore, carbon coatings can endow these nanoparticles with 
biocompatibility and a clear potential for further functionalization. It is enormously 
signiﬁcant for prospective biomedical applications [126]. 
Carbon-encapsulated magnetic nanoparticles (CEMNs) possess wide promising 
applications in magnetic recording media, seal liquid, magnetic inks for bank 
cheques, and biomedical applications such as magnetic resonance imaging (MRI) 
contrast agent, separation and concentration agent of biological samples [127]. 
S. Zhang et al. synthesized carbon coated Fe3O4 nanoparticles (Fe3O4/C) by a simple 
hydrothermal reaction and the particles were applied as solid-phase extraction (SPE) 
sorbents to extract trace polycyclic aromatic hydrocarbons (PAHs) from 
environmental water samples. The Fe3O4/C sorbents possess high adsorption 
capacity and extraction efﬁciency due to strong adsorption ability of carbon materials 
and large surface area of nanoparticles, and only 50 mg of sorbents are required to 
extract PAHs from 1000 mL water samples. Large surface area of nanomaterial and 
strong adsorption ability of carbon material result in high adsorption capacity and 
extraction efﬁciency to target compounds, therefore, satisfactory results were 
achieved using lower amount of Fe3O4/C nanoparticle sorbents than common 
sorbents [128]. 
P. Hojati-Talemi et al. prepared Fe3O4/carbon composite nanoparticles using 
polystyrene as the carbon source, with a household microwave oven providing the 
required energy to produce plasma in a partially-evacuated reaction vessel, leading to 
the high temperatures required for carbonization of the carbon source and formation 
of nanoparticles. In this process, magnetite nanoparticles actively catalyzed the 
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formation of carbon nanoﬁbers. The resulting composite retained the magnetic 
properties after this process, which is potentially very useful for producing new 
additives for electromagnetic shielding nanocomposites [129]. 
2.5 Characterization of Magnetic Nanoparticles 
2.5.1 Fourier transform infrared spectroscopy (FT-IR) 
FT-IR stands for Fourier Transform InfraRed, the preferred method of infrared 
spectroscopy. In infrared spectroscopy, IR radiation is passed through a sample. 
Some of the infrared radiation is absorbed by the sample and some of it is passed 
through (transmitted) (Fig. 2.20). FT-IR can identify unknown materials, determine 
the quality or consistency of a sample and the amount of components in a mixture 
[130]. 
 
Figure 2.20 : FT-IR mechanism [131]. 
Two types of interactions -absorption and transmission- are important in the typical 
IR experiment. When the molecule in the sample compartment of the spectrometer is 
exposed to a source of continuous IR radiation, the photons of discrete energy units 
that are absorbed by the molecule do not reach the detector. The IR spectrum reveals 
these missing photons, or absorptions, as a series of well-defined, characteristic, and 
reproducible absorption bands. Photons that are not absorbed by the sample are 
transmitted to the detector essentially unaltered. For a given wavelength or frequency 
of IR radiation striking a sample, these two interactions are inversely related through 
the following equation [132]: 
 A = log 1 / T (2.14) 
where: A = absorbance and T = transmittance  (% T/l00). 
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The resulting spectrum represents the molecular absorption and transmission, 
creating a molecular ﬁngerprint of the sample. Like a ﬁngerprint no two unique 
molecular structures produce the same infrared spectrum. This makes infrared 
spectroscopy useful for several types of analysis [130]. Absorption bands in the 
range of 4000 - 1500 wavenumbers are typically due to functional groups (e.g., -OH, 
C=O, N-H, CH3, etc.). The region from 1500 - 400 wavenumbers is referred to as the 
fingerprint region. Absorption bands in this region are generally due to 
intramolecular phenomena and are highly specific to each material. The specificity of 
these bands allows computerized data searches within reference libraries to identify a 
material [133]. 
The FT spectrometer works by splitting an IR beam into two. When these recombine, 
the light waves interfere constructively or destructively, creating the “interferogram” 
which is the time domain signal obtained from the detector. The interferogram must 
be analyzed with a computer using Fourier transforms to obtain a single-beam 
infrared spectrum that can be interpreted [134,133]. An IR spectrum displays 
detector response as percent transmittance (% T) on the y-axis, and IR frequency in 
terms of wavenumber (cm
-1
) on the x-axis. The detector response indicates the extent 
of interaction of the IR electromagnetic radiation with the sample as it is proportional 
to the resultant intensity of IR radiation that reaches the detector after passing 
through the sample [132]. From the Fig. 2.21, a simple spectrometer layout can be 
seen. 
 
Figure 2.21 : A simple spectrometer layout [130]. 
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2.5.2 X-ray powder diffraction (XRD) 
X-ray crystallography is a powerful and unambiguous method for the structural 
determination and characterization of crystalline substances: from simple salts and 
small molecules to complex proteins. There is no technique that can match the speed 
and reliability of single crystal X-ray diffraction for determining the structure of 
molecules in the solid state. It provides fast, reliable, secure access to small molecule 
crystal structure determination. Bragg‟s law refers to the simple equation [135]: 
 n λ = 2 d sinθ (2.15)  
English physicists Sir W.H. Bragg and his son Sir W.L. Bragg developed this 
relation in 1913 to explain why the cleavage faces of crystals appear to reflect X-ray 
beams at certain angles of incidence (theta, θ). The variable „dʼ is the distance 
between atomic layers in a crystal, and the variable lambda „λʼ is the wavelength of 
the incident X-ray beam; „nʼ is an integer. This observation is an example of X-ray 
wave interference, commonly known as X-ray diffraction (XRD), and was direct 
evidence for the periodic atomic structure of crystals postulated for several centuries 
[135]. 
About 95 % of all solid materials can be described as crystalline. When X-rays 
interact with a crystalline substance (phase), one gets a diffraction pattern. The X-ray 
diffraction pattern of a pure substance is like a fingerprint of the substance [136]. 
An electron in an alternating electromagnetic field will oscillate with the same 
frequency as the field. When an X-ray beam hits an atom, the electrons around the 
atom start to oscillate with the same frequency as the incoming beam. In almost all 
directions destructive interference will be had, that is, the combining waves are out 
of phase and there is no resultant energy leaving the solid sample. However the 
atoms in a crystal are arranged in a regular pattern, and in a very few directions 
constructive interference will be had. The waves will be in phase and there will be 
well defined X-ray beams leaving the sample at various directions. Hence, a 
diffracted beam may be described as a beam composed of a large number of 
scattered rays mutually reinforcing one another [136].  
Fig. 2.22 and 2.23 show the schemes for the basic XRD mechanism and X-ray 
scattering.  
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Figure 2.22 : XRD mechanism [131]. 
 
Figure 2.23 : Scattering of X-rays by a crystallite [137]. 
2.5.3 Transmission electron microscopy (TEM) 
Transmission electron microscopy is used to reveal sub-micrometre, internal ﬁne 
structure in solids [138]. It operates on the same basic principles as the light 
microscope but uses electrons instead of light [139] (Fig. 2.24).  
 
Figure 2.24 : TEM mechanism [131]. 
What you can see with a light microscope is limited by the wavelength of light. 
TEMs use electrons as "light source" and their much lower wavelength makes it 
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possible to get a resolution a thousand times better than with a light microscope. You 
can see objects to the order of a few angstrom (10
-10
 m). For example, you can study 
small details in the cell or different materials down to near atomic levels. The 
possibility for high magnifications has made the TEM a valuable tool in both 
medical, biological and materials research [139]. 
Electrons are one type of ionizing radiation, which is the general term given to 
radiation that is capable of removing the tightly bound, inner-shell electrons from the 
attractive field of the nucleus by transferring some of its energy to individual atoms 
in the specimen. One of the advantages of using ionizing radiation is that it produces 
a wide range of secondary signals from the specimen and some of these are 
summarized in Fig. 2.25 [140]. 
 
Figure 2.25 : Interaction of a high-energy beam of electrons with a thin  
 specimen and the resulting secondary signals [140]. 
As can be seen in the Fig. 2.25, signals generated when a high-energy beam of 
electrons interacts with a thin specimen [140]. These inelastic interactions between 
electrons and matter give different kinds of signals: secondary electrons, Auger 
electrons, X-rays, light and lattice vibrations. The X-ray energy corresponds to a 
difference between two energy levels of the electron cloud of an atom [141]. Most of 
these signals can be detected in different types of TEM. The directions shown for 
each signal do not always represent the physical direction of the signal, but indicate, 
in a relative manner, where the signal is strongest or where it is detected. In order to 
get the best signal out of the specimens one has to put the best signal in, and so the 
electron source is critical [140]. 
 49 
 
A transmission electron microscope is constituted of: (1) two or three condenser 
lenses to focus the electron beam on the sample, (2) an objective lens to form the 
diffraction in the back focal plane and the image of the sample in the image plane, 
(3) some intermediate lenses to magnify the image or the diffraction pattern on the 
screen [141]. 
A "light source" at the top of the microscope emits the electrons that travel through 
vacuum in the column of the microscope (Fig. 2.26). Instead of glass lenses focusing 
the light in the light microscope, the TEM uses electromagnetic lenses to focus the 
electrons into a very thin beam. The electron beam then travels through the 
specimen. Depending on the density of the material present, some of the electrons are 
scattered and disappear from the beam. At the bottom of the microscope the 
unscattered electrons hit a fluorescent screen, which gives rise to a "shadow image" 
of the specimen with its different parts displayed in varied darkness according to 
their density. The image can be studied directly by the operator or photographed with 
a camera [139]. 
 
Figure 2.26 : Electron column of a TEM [142]. 
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The amount and scale of the information which can be extracted by TEM depends 
critically on four parameters; the resolving power of the microscope (usually smaller 
than 0.3 nm); the energy spread of the electron beam (often several eV); the 
thickness of the specimen (almost always significantly less than 1 μm), and; the 
composition and stability of the specimen [138]. 
2.6 Applications of Magnetic Nanoparticles in Medicine 
Iron oxide particles such as magnetite (Fe3O4) or its oxidized form maghemite (γ-
Fe2O3) are by far the most commonly employed in biomedical applications since 
their biocompatibility has already been proven [17], (Fig. 2.27). 
 
Figure 2.27 : General scheme of the different applications for magnetic 
 nanoparticles (adapted from M. Arruebo et al., 2009) [143]. 
Fe3O4 has been widely studied in recent years due to its interesting magnetic 
properties and many potential applications, especially being an ideal candidate for 
biological applications [96]. In order that Fe3O4 nanoparticles exhibit required 
magnetic efﬁciency in biomedical applications, Fe3O4 nanoparticles should have the 
controlled size suitable for them because the magnetic properties depend strongly on 
the particle size. For example, Fe3O4 nanoparticles of about 10–20 nm are used for 
DDS (drug delivery system) and cancer therapy, and below 10 nm of 
superparamagnetic Fe3O4 nanoparticles with good dispersibility are needed for MRI 
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[49]. Though magnetic nanoparticles with different compositions, sizes and shapes 
have been developed for biomedical applications [16]. Thus, with these excellent 
properties, magnetite (Fe3O4) nanoparticles are suitable for biomedical applications, 
such as targeted drug delivery, MRI contrast enhancement, cancer diagnosis, 
hyperthermic treatment of tumors, and magnetically mediated separation of 
biomolecules [98]. 
2.6.1 Targeted drug delivery 
Due to their small size, nanoparticles are particularly promising carriers for drug 
delivery systems used in cancer treatment. Such drug delivery systems increase the 
efﬁciency of chemotherapy and reduce the side effects [144]. 
The importance of targeted drug delivery and targeted drug therapy is to transport a 
drug directly to the centre of the disease under various conditions and thereby treat it 
deliberately, with no effects on the body [81]. Targeting of drugs by nanoparticles is 
intended to reduce drug wastage, frequency of drug administration, side effects 
providing prolonged, sustained drug delivery to desired targeted organ. Iron oxide 
magnetic nanoparticles present a higher performance in terms of chemical stability 
and biocompatibility compared with metallic nanoparticles. Nanoparticles have a 
large surface that may be properly modified to attach biological agents [145]. 
In magnetically targeted drug delivery, carriers comprising of coated magnetic 
nanoparticles loaded with anti-cancer drug are injected into the patient body via the 
human circulatory system. An external magnetic field is used to localize the drug 
loaded carriers at the tumor site and the drug can then be released from the carriers 
either via enzymatic activity or changes in physiological conditions such as pH, 
osmolality, or temperature and be taken up by tumor cells. Alexiou et al. showed that 
this magnetic targeted drug delivery caused complete tumor remission in tumor 
bearing rabbits without any negative side effects and the applied dose of drug 
reduced to 20 % of the regular systemic dose. A Phase-I human clinical trial with 4-
epidoxorubicin showed encouraging results of the physiological tolerance of 
magnetic drug targeting by patients [146]. 
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2.6.2 Hyperthermia cancer treatment 
Magnetic nanoparticles can be utilized not only as carriers for drug delivery systems 
but also as heat sources for hyperthermia, which is a heat treatment for cancer that 
poses a low risk to the body and causes few side effects as compared to traditional 
cancer treatments such as surgery, chemotherapy, and radiation therapy [144]. 
Magnetic particles in a solution undergo two types of relaxation: Brownian 
relaxation, in which the entire particle rotates, and Néel relaxation, in which the 
moment rotates while the particle remains still [65]. When magnetic nanoparticles 
are subjected to an alternating magnetic field, heat can be generated by Néel 
relaxation, Brownian relaxation and hysteresis losses [146].  
Hyperthermia is the heating of cells in the range of 41–47°C, which causes 
preferential death of tumor cells [146]. The method relies on the theory that any 
metallic objects when placed in an alternating magnetic field will have induced 
currents flowing within them. The amount of current is proportional to the size of the 
magnetic field and the size of the object. As these currents flow within the metal, the 
metal resists the flow of current and thereby heats, a process termed inductive 
heating. If the metal is magnetic, such as iron, the phenomenon is greatly enhanced. 
Therefore, when a magnetic fluid is exposed to an alternating magnetic field the 
particles become powerful heat sources, destroying the tumour cells. The magnetic 
fluids used are preferably suspensions of superparamagnetic particles, prepared much 
as described for MRI contrast agents, as these produce more heat per unit mass than 
larger particles. The level heating is simply controlled by the materials Marie Curie 
temperature, that is, the temperature above which materials lose their magnetic 
properties and thus their ability to heat [20]. 
The inevitable technical problem with hyperthermia is the difﬁculty in heating only 
the local tumor region to the intended temperature without damaging the surrounding 
healthy tissue. Fe3O4 nanoparticles have been used for hyperthermia treatment in an 
attempt to overcome this obstacle [96]. 
2.6.3 Magnetic resonance imaging (MRI) 
The magnetic nanoparticles are especially useful in biomedicine when they are 
dispersed into water to form ferrofluids, which can be used, for example, as image 
contrast agents in magnetic resonance imaging (MRI) [147]. Fe3O4 MNPs possess 
 53 
 
superparamagnetism which are suitable for MR contrast enhancement by alterations 
of proton relaxation in the tissue microenvironment [105]. 
MRI scans yield high-quality anatomical images for clinical diagnosis, pre-surgical 
assessment, and therapy monitoring. The technique works by applying a series of 
short-lived radio frequency (RF) pulses to a body placed within a constant magnetic 
field. Measured changes in the magnetization of hydrogen protons in water 
molecules are used to derive a picture of anatomical structures. So-called „contrast 
agents‟, which alter the behavior of nearby molecules, can be administered to 
sharpen image detail [148]. 
In standard clinical MRI scans contrast agents travel through the bloodstream and 
tissues, increasing contrast wherever they go. Although the more commonly used 
MR contrast media are gadolinium (Gd) chelates, these tend to be non-specific with 
rapid accumulation in the liver, thus they only allow a short time imaging window. 
Colloidal iron oxides therefore play an important role as MRI contrast agents, as 
superparamagnetic iron oxide particles were the first liver-specific contrast agents 
used. It has been known for many years that the inclusion of magnetic particles 
within tissue enables a very large signal to be obtained from a MRI scanner [20]. 
MNPs can remain for longer periods in tissue than compared to common contrast 
agents. This has the added benefit of reducing the quantity of contrast agent to be 
administered to the patient thus minimizing any adverse toxic effects. In addition, it 
is possible to take more scans after administration resulting in an overall 
enhancement of the MRI contrast. Due to the polymer coating, MNPs possess longer 
blood circulation times which improve the efficiency of detection of the cancer cells. 
Furthermore, the possibility to add bioactive functional groups at the surface of the 
particles (such as enzymes, peptides, antibodies and various antagonists) allows the 
specific cell targeting of the MNPs in the organism. Finally, the MNPs are more 
selective and more specific than other contrast agents which improves MRI results 
[149]. 
2.6.4 Bioseparation processes 
Separation of speciﬁc biological entities from their environments is very important in 
biochemical analysis and disease diagnosis [16]. Fe3O4 particles exhibit 
superparamagnetic behavior at room temperature. In other words, they magnetize 
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strongly under an applied magnetic ﬁeld but retain no permanent magnetism once the 
ﬁeld is removed [98]. This magnetic on/off switching behavior is extremely helpful 
for magnetic separation [16]. 
Magnetic separation is a well-developed method and can be used as an alternative to 
the conventional centrifugal separation method. A typical magnetic separation 
procedure mainly consists of four steps, and iron oxide particles are often used in 
magnetic separation. In the ﬁrst step, magnetic microbeads are made by encasing 
iron oxide nanoparticles in a biocompatible coating, and the surface of the 
microbeads is functionalized with a special biological or chemical agent that can 
selectively bind to the target cells or molecules to be separated. In the second step, 
the functionalized microbeads are added to the solution containing the target cells or 
molecules, and the target cells or molecules are subsequently bound to the magnetic 
microbeads. In the third step, a permanent magnet is placed at the side of the 
solution, inducing a magnetic moment on the magnetic microbeads and establishing 
a magnetic ﬁeld gradient which drives the magnetized microbeads to move along the 
ﬁeld lines. Finally, the magnetized microbeads cluster together near the magnet, and 
thus the target cells or molecules bound to the magnetic microbeads are separated 
[16]. 
Various biological molecules such as antibodies, proteins, targeting ligands, etc., 
may also be bound to the polymer surfaces onto the nanoparticles by chemically 
coupling via amide or ester bonds to make the particles target specific [21], (Fig. 
2.28).  
When conjugated with biomolecules such as antibodies, biotin and enzyme and so 
on, the MNPs could form lock-and-key interactions with target molecules of antigen, 
streptavidin and substrate, respectively. Therefore, adequate amount of biomolecules 
and biological activity on the surface of MNPs is the key of their specific recognition 
and target capability [150].  
MNPs can be further derivatised with non-specific moieties (ionic, hydrophobic, 
hydrogen bond), group specific (dye ligand, immobilized metal affinity 
chromatography, or chelating), or highly specific ligands (antigen-antibody, avidin-
biotin, enzyme-inhibitor, etc). An overview of viable surface anchoring groups is 
represented in Fig. 2.29 [149]. 
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Figure 2.28 : Examples of magnetic nanoparticles coated with polysaccharides  
and decorated with multifunctional receptors [149]. 
 
Figure 2.29 : Common chemical moieties for the anchoring of  
polymers and functional groups at the surface of  
 magnetic nanoparticles [149]. 
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The application of magnetic particles (sub-micron to 10 μm) in separation processes 
permits fast and cost effective separation of the target biomolecule from the reaction 
mixture without filtration or centrifugation, therefore representing a gentle, scalable, 
versatile and easy to automate separation process [149].  
Magnetic separation has wide application in biotechnology and biomedicine, such as 
immunomagnetic cell separation and purification, immunoassays, isolation, 
purification and recognition of proteins. In molecular biology, it can be used for 
DNA/RNA purification. In addition, the isolation and detection of microorganisms is 
easily possible using magnetic separation [17]. 
2.6.4.1 Immunomagnetic separation 
Immunomagnetic separation has become an essential tool for high-throughput and 
low-cost isolation of biomolecules and cells from heterogeneous samples [151]. With 
surface modification, magnetic nanoparticles have been labeled with a variety of 
biological molecules that have the ability to scavenge for targets of interest and 
separate them from complex biological media [152]. Antibodies, for example, 
specifically bind to their antigen, providing an effective means of tagging [65].  
Antibodies are nanosize biological products that are part of the specific immune 
system. In addition to their own properties as pathogens or toxin neutralizers, as well 
as in the recruitment of immune elements (complement, improving phagocytosis, 
cytotoxicity antibody dependent by natural killer cells, etc.), they could carry several 
elements (toxins, drugs, fluorochroms, or even nanoparticles, etc.) and be used in 
several diagnostic procedures, or even in therapy to destroy a specific target [143]. 
A typical antibody molecule (the prototype class of immunoglobulin is IgG) is made 
up of four polypeptide chains with a molecular weight of about 150 kD. The four 
chains are divided into two identical light chains and two identical heavy chains 
[153], (Fig. 2.30).  
A heavy chain has three regions that affect recognition, variable (V), diversity (D), 
and joining (J). A light chain has only the V and J regions. In humans, there are 
approximately one hundred different V genes, twelve D genes, and four J genes 
[154]. 
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Figure 2.30 : The coding and assembly of antibody molecules [154]. 
An antibody molecule is Y-shaped, with two identical antigen-binding sites at the 
ends of the arms of the Y. The light and heavy chains contribute to the antigen-
binding sites. Each antibody molecule can bind to two identical antigenic 
determinants. Where the arms meet, the stem of the Y is known as the hinge region. 
The hinge region allows segmental flexibility of the antibody molecule. The two 
antigen-binding ends (or amino-terminal ends) of the antibody molecule are called 
the Fab fragments (for fragment antigen binding), whereas the stem (or carboxyl-
terminal end) of the Y is considered to be the Fc fragment (for fragment 
crystallizable). The Fc region of the antibody molecule is responsible for its biologic 
properties, which include activation of the complement system (leading to enhanced 
phagocytosis), placental transfer, and binding to cell-surface receptors [153]. 
Specific host immunity recognizes and binds to an epitope, which is a small 
molecular site within a larger parasite molecule. An antigen is a parasite molecule 
that stimulates a specific immune response because it contains one or more epitopes. 
For example, if one injects a large foreign protein into a host, the host recognizes 
thousands of different epitopes on the surface of the protein antigen [154].  
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In medical and clinical diagnostics, the interaction of antigens and antibodies is 
routinely used to measure concentrations of biological markers [155]. Most often, a 
monoclonal antibody (MAb) is used for immunomagnetic separation [156]. 
Monoclonal antibodies were the first targeting agents to exploit molecular 
recognition to deliver magnetic nanoparticles and continue to be widely used due to 
their high specificity [157].  
Magnetic particles carrying specific antibody can be used for the capture of target 
cells and their separation from the environment [158]. Bioconjugation can take place 
by means of adsorption (at the isoelectrical point of the antibody via electrostatic 
interaction), by direct covalent linkage between the surface of the nanoparticle and 
the antibody. Optimal bioconjugation would involve the covalent attachment of the 
antibody through the Fc (fragment: crystallizable) region, leaving the antigen-
binding site Fab (fragment: antigen binding) region oriented to the medium to 
preserve its full function, and in a ratio of one to one to allow a direct quantification. 
The conjugation of antibodies to nanoparticles can generate a product that combines 
the properties of both. For example, they can combine the small size of nanoparticles 
and their special thermal, imaging, drug carrier, or magnetic characteristics with the 
abilities of antibodies, such as specific and selective recognition [143]. 
A simple representation of immunomagnetic separation of targeted molecules is 
shown in Fig. 2.31. 
 
Figure 2.31 : Scheme diagram of immunomagnetic separation of targeted molecules 
(adapted from Dynal information booklet, 2010) [159]. 
As indicated in Fig. 2.31, immunomagnetic separation process mainly consists of 
three steps: first, the surface of the magnetic nanoparticles is anchored with 
antibodies which are against targeted antigens, and immunomagnetic nanoparticles 
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(antibody conjugated magnetic nanoparticles) are obtained. Second, these 
immunomagnetic nanoparticles are mixed with the suspension containing targeted 
molecules (antigens) to be separated. Finally, after forming antibody-antigen 
complexes, a magnetic field is applied to the suspension, and the immunomagnetic 
nanoparticles with the targeted molecules on them are separated from the rest of the 
sample. Then, all other substances are washed out easily. In the further step, a 
suitable solution to uncouple targeted molecules from antibodies is used together 
with a magnet, and the targeted molecules are obtained. The covalent bond between 
magnetic particle and antibody allows one to perform the regeneration of 
immunomagnetic nanoparticles without any significant loss of the binding capacity. 
So, after washing step, the immunomagnetic nanoparticles can be stored and used for 
further separation processes. 
The number of papers in databases such as PubMed, employing the principle of 
immunomagnetic separation, is approaching 1000 and is rapidly increasing [156]. As 
an example, biotin-labelled polyclonal goat anti-Escherichia coli antibodies have 
been attached to streptavidin-coated magnetic nanoparticles, and used for the 
separation and selective quantification of Escherichia coli O157:H7 in ground beef 
in the presence of other bacteria [143].  
H. Xu et al. demonstrated a highly efficient process using iron oxide magnetic 
nanoparticles-based immunomagnetic separation of tumor cells from fresh whole 
blood. The process involved polymer coated 30 nm iron oxide magnetic 
nanoparticles that was modified with antibodies (Ab) against human epithelial 
growth factor receptor 2 (anti-HER2 or anti-HER2/neu) forming iron oxide magnetic 
nanoparticles-antibody [160].  
C.E. Probst et al. reported a rapid multitarget immunomagnetic separation 
technology that combined the extensive multiplexing capacity of DNA-antibody 
conjugates and the high selectivity, throughput, and simplicity of magnetic isolation 
by employing a unique approach involving strand-mediated displacement (SMD) of 
DNA linkers [151]. W. Chen et al. prepared immunomagnetic nanoparticles by 
covalently immobilizing anti-CD34
+
 monoclonal antibodies to the surface of amino 
silane modified magnetic particles. The cell separation results showed that the 
synthesized immunomagnetic nanoparticles could rapidly and conveniently separate 
the CD34
+
 cells with high efficiency and specificity than normal ones [161]. 
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3. EXPERIMENTAL PART 
3.1 Substances 
Table 3.1 : Chemicals and reagents. 
Name Purity Producer 
Iron(II) sulfate heptahydrate, 
FeSO4.7H2O 
≥ 99 % 
Sigma-Aldrich, 
USA 
Iron(III) chloride hexahydrate, 
FeCl3.6H2O 
≥ 99 % 
Sigma-Aldrich, 
USA 
Ammonium hydroxide solution,  NH4OH 25 % 
Lach-Ner, Czech 
Republic 
Oleic acid, C18H34O2 ≥ 98 % 
Lachema, Czech 
Republic 
Chitosan 
medium 
molecular 
weight 
Aldrich, USA 
Glutaric dialdehyde (Glutaraldehyde, 
OHC(CH2)3CHO) 
50 % wt. 
solution in water  
Sigma-Aldrich, 
USA 
8-iso Prostaglandin F2α EIA Antiserum 100 % 
Cayman 
Chemical, USA 
Cysteinyl Leukotriene EIA Monoclonal 
Antibody 
LTC4 – 100 % 
LTD4 – 100 % 
LTE4 – 79 % 
Cayman 
Chemical, USA 
Sodium dihydrogen phosphate 
monohydrate, H2NaO4P.H2O 
≥ 99 % Fluka, USA 
Sodium phosphate dibasic dihydrate,  
Na2HPO4.2H2O 
≥ 99.5 % 
Riedel-deHaën, 
Germany 
Sodium chloride, NaCl ≥ 99 %  Aldrich, USA 
Albumin from bovine serum (BSA)  
further purified 
Fraction V 
Sigma, USA 
alpha,alpha,alpha-Tris-(hydroxymethyl)-
methylamin, (HOCH2)3CNH2 
≥ 99.9 % Aldrich, USA 
Sodium azide, NaN3 ≥ 99 % Aldrich, USA 
8-iso Prostaglandin F2α > 99% 
Cayman 
Chemical, USA 
Cysteinyl-Leukotriene HPLC Mixture I 
(LTC4, LTD4, LTE4) 
≥ 98% for each 
compound 
Cayman 
Chemical, USA 
Glycine, C2H5NO2 ≥ 99 %  Sigma, USA 
Dynabeads M-280 Tosylactivated research grade 
Dynal Biotech 
ASA, Norway 
 62 
 
Table 3.1 (continued): Chemicals and reagents.  
Name Purity Producer 
Leukotriene C4-d5 ≥ 99 % Cayman Chemical, USA 
Leukotriene D4-d5 ≥ 99 % Cayman Chemical, USA 
Leukotriene E4-d5 ≥ 99 % Cayman Chemical, USA 
8-iso Prostaglandin F2α-d4 ≥ 99 % Cayman Chemical, USA 
Table 3.2 : Solvents. 
Name Purity Producer 
Water Deionized Watrex, Czech Republic 
Water LC/MS quality Fisher Scientific, USA 
Nitric acid,  HNO3 65 % Lach-Ner, Czech Republic 
Acetone,  C3H6O 99.97 % Lach-Ner, Czech Republic 
Acetic acid,  C2H4O2 99.8 % Fisher Scientific, USA 
Ethanol,  C2H6O HPLC quality Merck, Germany 
Hydrochloric acid, HCI 35 % Lach-Ner, Czech Republic 
Acetonitrile 99.9 % Fisher Scientific, USA 
Table 3.3 : Buffers. 
Name Preparation 
Buffer A (0.1 M Phosphate 
Buffer, pH 7.4) 
0.262 g NaH2PO4.H2O and 
1.442 g Na2HPO4.2H2O 
are dissolved in 100 mL water 
Buffer B (PBS Buffer, pH 7.4 
with 0.1 % (w/v) BSA) 
0.88 g NaCI and 0.1 g BSA are dissolved 
in 10 mL of 0.01 M phosphate buffer, and 
then diluted to 100 mL with water 
Buffer C (0.2 M TRIS, pH 8.5 
with 0.1 % (w/v) BSA) 
2.42 g TRIS is dissolved in 50 mL water, 
and the pH is adjusted to 8.5 with 1 M 
HCI. Then, 0.1 g BSA is added and 
dissolved in the solution. Finally, it is 
diluted to 100 mL with water 
Buffer D (PBS Buffer, pH 7.4 
with 0.5 % (w/v) BSA) 
0.88 g NaCI and 0.5 g BSA are dissolved 
in 50 mL of 0.01 M phosphate buffer, and 
diluted to 100 mL with water 
Table 3.4 : Gases. 
Name Purity Producer 
Argon technical 4.6 SIAD, Czech Republic 
Nitrogen technical 4.0 SIAD, Czech Republic 
Air technical SIAD, Czech Republic 
 
 63 
 
3.2 Instruments and Materials 
3.2.1 Fourier transform infrared spectroscopy (FT-IR) 
Infrared spectra were measured on FTIR spectrometer Nicolet 6700. Measuring 
technique was attenuated total reflectance (ATR) with single reflection ATR 
diamond crystal (GladiATR, PIKE Technologies, USA). The spectral range of the 
measurement was 4000 – 400 cm-1 with the resolution 4 cm-1 and number of spectra 
accumulation 64 and Happ-Genzel apodization. Spectra were processed by Omnic 
7.3 (Nicolet Instruments Co., USA) program. 
3.2.2 X-ray powder diffraction (XRD) 
X-ray powder diffraction was measured on two types of instruments: (1) θ-θ powder 
difractometer X'Pert PRO (PANalytical, the Netherlands) and (2) θ-θ powder 
difractometer Bruker AXS D8 (Bruker AXS, USA). Measurement was done on θ-θ 
powder diffractometer X'Pert PRO in Bragg-Brentano parafocusing geometry with 
the use of CuKα radiation (λ = 1.5418 Å, U = 40 kV, I = 30 mA) at room 
temperature. Data were scanned by ultrafast X'Celerator detector (or scintillation 
detector with secondary curved monochromator) in the angle range 5-60° (2θ) with 
the measuring step 0.02° (2θ) and frequency of measuring 0.3 s/step. Data were 
evaluated with the use of HighScore Plus program. 
Data were also measured on θ-θ powder diffractometer Bruker AXS D8 in Bragg-
Brentano parafocusing geometry with the use of CoKα radiation (λ = 1.79021Å, U = 
34 kV, I = 20 mA) at room temperature. Data were scanned by ultrafast LynxEye 
detector in the angle range 10-80° (2θ) with the measuring step 0.0196° (2θ) and 
frequency of measuring 19.2 s/step. Data were evaluated with the use of HighScore 
Plus program and the size of the particles was calculated from the width in the half of 
the peak. 
3.2.3 Transmission electron microscopy (TEM) 
Samples were viewed under a Philips CM100 electron microscope (FEI, formerly 
PEO Eindhoven, the Netherlands) at 80 kV. Digital images were recorded using a 
MegaView II slow scan camera (Olympus, formerly SiS GmbH, Germany) at a 
primary magnification ranging from 64,000× to 92,000× giving pixel size of 1 nm or 
0.7 nm, respectively. Recorded images were processed in AnalySis 3.2 software. 
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3.2.4 Liquid chromatography–mass spectrometry (LC-MS) 
The analysis of the substances were carried out on the LC-MS system consisting of 
degaser with pump and autosampler Accela (Thermo Fisher Scientific, USA) and 
mass spectrometer with triple stage quadrupole analyzer - TSQ Vantage (Thermo 
Fisher Scientific, USA) with electro-spray ionization (H-ESI). Fig. 3.1 shows the 
mass spectrometry combined with the liquid chromatography used in the laboratory. 
 
Figure 3.1 : LC-MS system. 
3.2.5 Commercially available magnetic particles (Dynabeads M-280 
Tosylactivated) 
Dynabeads M-280 Tosylactivated are uniform, superparamagnetic, polystyrene beads 
coated with a polyurethane layer. They have diameters of 2.8 μm, a surface area of 4-
8 m
2
/g, a density of 1.4 g/cm
3
 and an active chemical functionality of 0.1-0.2 mmol/g 
Dynabeads [162] (Fig. 3.2).  
 
Figure 3.2 : Dynabeads M-280 Tosylactivated [159]. 
 65 
 
The hydroxy groups are activated by reaction with p-toluensulphonyl chloride. The 
resulting sulphonyl ester can subsequently react covalently with proteins or other 
ligands containing amino or sulfhydryl groups. Dynabeads M-280 Tosylactivated 
will bind proteins physically and chemically with an increasing number of covalent 
bonds with higher temperature and pH [162]. 
Dynabeads M-280 Tosylactivated is a solid-phase designed for biomagnetic 
separations. Any ligand (e.g. antibody, protein, peptide or glycoprotein) containing 
amino or sulfhydryl groups can be covalently coupled to the surface of the beads 
(Fig. 3.3) [162].  
 
Figure 3.3 : Ligand coupling protocol for Dynabeads M-280 Tosylactivated [162]. 
The combination of specific antigens or antibodies and the superparamagnetic 
properties of the Dynabeads ensure rapid reaction kinetics both in the binding 
process and in the separation of the analyte [162]. 
In this study, apart from the synthesized magnetic Fe3O4–chitosan nanoparticles, 
antibodies were also conjugated to the Dynabeads M-280 Tosylactivated. 
3.2.6 Other apparatus and equipments 
• Overhead stirrer, IKA EUROSTAR power basic (IKA-Werke GmbH & Co. KG, 
Germany) 
• Magnetic stirrer, IKA C-MAG HS 7 (IKA-Werke GmbH & Co. KG, Germany) 
• Shaker, IKA MS 3 digital (IKA-Werke GmbH & Co. KG, Germany) 
• Shaker, IKA KS 130 basic (IKA-Werke GmbH & Co. KG, Germany) 
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• Minishaker, IKA MS 2 (IKA-Werke GmbH & Co. KG, Germany) 
• Magnet with 6 tube-holder plastic rack, Dynal MPC-S (Dynal Biotech ASA,   
Norway) 
• Ultrasonic bath, Bandelin Sonorex Digitec DT 102 H (Bandelin GmbH & Co. KG, 
Germany) 
• pH meter, CyberScan pH 510 (Eutech Instruments Pte Ltd, Singapore) 
• Adjustable-volume pipettes in different sizes (Eppendorf AG, Germany) 
• Eppendorf tubes (1.5-2 mL) and tips (Eppendorf AG, Germany) 
3.3 Preparation of Magnetic Fe3O4 Nanoparticles with Oleic Acid 
The magnetite, Fe3O4 (FeO.Fe2O3) magnetic nanoparticles were synthesized by co-
precipitation of Fe(II) and Fe(III) solutions in base medium for using in the 
preparation of chitosan functionalized magnetic nanoparticles (Fe3O4–chitosan 
nanoparticles). Oleic acid was used for stabilization, preventing the agglomeration 
among the nanoparticles. Equation (3.1a) and (3.1b) show the overall reaction of 
Fe3O4: 
 FeSO4 + 2FeCl3 + 8NH4OH → Fe3O4 + (NH4)2SO4 + 6NH4Cl + 4H2O (3.1a) 
 Fe
+2
 + 2Fe
+3
 + 8OH
–
 ↔ Fe(OH)2 + 2Fe(OH)3 → Fe3O4 + 4H2O (3.1b)  
In the procedure, 0.9 g FeSO4.7H2O was dissolved in 8.75 mL deionized water and 
1.7 g FeCl3.6H2O was dissolved in 10 mL deionized water with the mole ratio of 
Fe
+2
/Fe
+3 
= 1/2. The iron solutions were mixed together and transferred into a 250 
mL three-necked ﬂask which was placed into an oil-bath. Then 4.4 mL of ammonium 
hydroxide solution (NH4OH) and 0.4 mL oleic acid were added into the solution 
quickly under a vigorous stirring by a shaft mixer (overhead stirrer). The mixture 
was stirred for 1 hour at room temperature. After 1 hour the temperature was 
increased to 95°C. When 95°C was achieved and the reaction was completed, the 
flask was removed from the oil-bath and cooled to room temperature. The pH of the 
mixture was measured and adjusted to ~5 with HNO3:H2O (1:5) solution.  
The supernatant was separated from the resulting black precipitates of magnetite by 
decantation with the help of a strong magnet, and the oleic acid modified magnetic 
Fe3O4 nanoparticles were collected through magnetic separation. Then the particles 
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were washed 4 times with deionized water and 4 times with acetone in order to 
remove non-binding components. The products were stored in acetone. Fig. 3.4 
shows the flowchart of the synthesis of the oleic acid modified magnetic Fe3O4 
nanoparticles by co-precipitation.  
 
Figure 3.4 : Flowchart of the synthesis of the magnetic Fe3O4 nanoparticles  
by co-precipitation. 
A schematic illustration for the formation of the oleic acid modified magnetic Fe3O4 
nanoparticles is shown in Fig. 3.5. 
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1 h stirring, 25°C
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Fe3O4
Washing with water 
and acetone /
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Figure 3.5 : Scheme for the oleic acid modified magnetic Fe3O4  
nanoparticles (adapted from J. Qu et al., 2010) [89]. 
3.4 Functionalization of Fe3O4 Nanoparticles with Chitosan and Glutaraldehyde 
For the functionalization of the magnetic Fe3O4 nanoparticles with chitosan and 
glutaraldehyde, first 0.25 g chitosan was dissolved in 50 mL of 1.0 wt% acetic acid 
solution and 0.75 g dry, oleic acid modified magnetic Fe3O4 nanoparticles were 
weighed. The Fe3O4 nanoparticles and the chitosan solution were added into a 100 
mL flask. The flask was placed into an ultrasonic bath and the dispersion medium in 
the flask was treated with ultrasonic agitation for 10 min at room temperature. After 
10 min, the flask was placed on a mechanical shaker and stirred for 20 min more. 
Then, an additional 1 mL of 25 wt% glutaraldehyde solution was added into the 
mixture as cross-linker, and the flask was placed into a water-bath which was set on 
a hot-plate magnetic stirrer. The cross-linking reaction between chitosan and 
glutaraldehyde was kept for 3 hours at 40°C under magnetic stirring. After the 
completion of the reaction, the supernatant was separated by decantation with the 
help of the magnet, and the magnetic Fe3O4–chitosan nanoparticles were collected 
through magnetic separation. Then the particles were washed 4 times with deionized 
water and 4 times with ethanol in order to remove non-binding components. The 
products were stored in ethanol. Fig. 3.6 shows the flowchart of the preparation of 
magnetic Fe3O4 nanoparticles functionalized with chitosan and glutaraldehyde. 
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Figure 3.6 : Flowchart of the preparation of the magnetic  
 Fe3O4–chitosan nanoparticles. 
A schematic illustration for the formation of the magnetic Fe3O4–chitosan 
nanoparticles is shown in Fig. 3.7.  
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Figure 3.7 : Scheme for the chitosan functionalized magnetic Fe3O4  
  nanoparticles (adapted from J. Qu et al., 2010) [89]. 
3.5 Anchoring Antibody onto the Surface of Magnetic Fe3O4–Chitosan 
Nanoparticles 
For immobilizing antibodies on the surface of the magnetic Fe3O4–chitosan 
nanoparticles, approximately 1 mg of magnetic Fe3O4–chitosan nanoparticles were 
weighed and put into an Eppendorf tube. To wash the particles, 200 μl of Buffer A 
was added into the tube and the tube was vortexed in a minishaker for 5 min. After 5 
min, the tube was placed in the magnet (with holders) and the supernatant was 
removed by pipetting out and the particles were isolated from the liquid part. The 
washing procedure was repeated twice. After the washing step, 100 μl (could be at 
different amounts according to the experiment) antibody (against cysteinyl 
leukotrienes or 8-iso Prostaglandin F2α according to the experiment) and 400 μl of 
Buffer A were added to the Fe3O4–chitosan nanoparticles. The tube was placed in the 
minishaker and vortexed for 20 hours. After 20 hours, the tube was placed in the 
magnet and the supernatant was removed by pipetting out, and the particles were 
washed in order to remove non-binding components. In the washing procedure, 200 
μl of Buffer D was added into the tube and it was vortexed in the minishaker for 10 
min. After 10 min, the tube was placed in the magnet and the supernatant was 
removed by pipetting out, and the antibody anchored magnetic Fe3O4–chitosan 
nanoparticles (immunomagnetic nanoparticles) were isolated from the liquid part. 
The washing procedure with Buffer D was repeated 4 times. The immunomagnetic 
nanoparticles were stored in 0.02 % sodium azide (NaN3) solution prepared in Buffer 
A.  
A schematic illustration for anchoring antibody onto the surface of the magnetic 
Fe3O4–chitosan nanoparticles is shown in Fig. 3.8.  
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Figure 3.8 : Scheme for the formation of the immunomagnetic nanoparticles 
(adapted from K. Syslová et al.) [2]. 
3.6 Anchoring Antibody onto the Surface of Dynabeads M-280 Tosylactivated 
The procedure for immobilizing antibodies on the surface of the Dynabeads M-280 
Tosylactivated differs little from the procedure for immunomagnetic nanoparticles. 
To prepare antibody anchored Dynabeads, 30 μl (~42 mg) of Dynabeads solution 
was put into an Eppendorf tube and the tube was placed in the magnet (with holders) 
and the supernatant was removed by pipetting out, and the Dynabeads were isolated 
from its liquid part. To wash the particles, 200 μl of Buffer A was added into the tube 
and the tube was vortexed in the minishaker for 5 min. After 5 min, the tube was 
placed in the magnet and the supernatant was removed again, and the particles were 
isolated from the liquid part. The washing procedure was repeated 3 times. After the 
washing step, 100 μl antibody against Cys-LTs and 400 μl of Buffer A was added to 
these washed Dynabeads. The tube was placed in the minishaker and vortexed for 24 
hours. After 24 hours, the tube was placed in the magnet and the supernatant was 
removed, and the particles were washed in order to remove non-binding components. 
In the washing procedure, the Dynabeads were first washed 2 times with 200 μl of 
Buffer B, each vortexing for 5 min. After removing the second supernatant, 200 μl of 
Buffer C was added into the tube and it was vortexed for 4 hours. After 4 hours, the 
tube was placed in the magnet and the supernatant was removed. As the final 
washing step 200 μl of Buffer B was added into the tube and it was vortexed for 5 
min. After 5 min, the tube was placed in the magnet and the supernatant was 
removed, and the antibody anchored magnetic Dynabeads were isolated from the 
liquid part. The resulting immunomagnetic Dynabeads were stored in 0.02 % sodium 
azide (NaN3) solution prepared in Buffer B.  
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3.7 Formation of Antibody-Antigen Complexes 
The immunomagnetic particles were used to separate Cys-LTs and 8-iso PGF2α 
(essential biomarkers of asthma and oxidative stress, respectively) from biological 
matrices like exhaled breath condensate (EBC). These biomarker molecules were 
treated like antigens in this study. The principle of the immunomagnetic separation 
method was based on forming antibody-antigen (antibody-biomarker) complexes on 
the surface of the particles and isolating these complexes by applying an external 
magnetic field. In the procedure, first the immunomagnetic particles, which were 
already in the Eppendorf tubes, were washed 3 times with 500 μl of Buffer A, each 
vortexing for 5 min. After the washing step, the tube was placed in the magnet and 
the supernatant was removed by pipetting out. A sample containing biomarkers (Cys-
LTs or 8-iso PGF2α, at different concentrations according to the experiment) was 
prepared and added to the particles. Then the tube was vortexed in the minishaker for 
1 hour. After 1 hour vortexing, antibody-antigen complexes were formed. The tube 
was placed in the magnet and the supernatant was removed by pipetting out, and the 
particles were washed 3 times with 1 mL of HPLC quality water in order to remove 
non-binding components (each vortexing for 5 min). After the last washing step, the 
supernatant was removed again by pipetting out and the immunomagnetic particles 
with the antibody-antigen complexes on them were isolated from the liquid part.  
A schematic illustration for forming antibody-antigen complexes on the 
immunomagnetic nanoparticles is shown in Fig. 3.9. 
 
Figure 3.9 : Scheme for formation of antibody-antigen complexes  
(adapted from K. Syslová et al.) [2]. 
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3.8 Separation of Antigens from Antibody-Antigen Complexes 
In order to uncouple the antigens (Cys-LTs and 8-iso PGF2α) from the antibodies 
(and thus from the immunomagnetic nanoparticles or the immunomagnetic 
Dynabeads) by breaking the bonds between them, 100 mmol/L glycine solution was 
used. To prepare this solution 0.075 g glycine was weighed and dissolved in 10 mL 
water. 100 μl of this solution was added to the immunomagnetic particles having 
antibody-biomarker complexes on them. The tube was vortexed in the minishaker for 
10 min. After 10 min, the biomarkers (Cys-LTs/8-iso PGF2α) were uncoupled from 
the antibodies and released to the liquid part (glycine solution). The tube was placed 
in the magnet once again, but this time the liquid part containing Cys-LTs/8-iso 
PGF2α was separated from the immunomagnetic particles by pipetting out. The 
amount of the biomarkers in this sample was measured by LC-MS. After washing, 
the immunomagnetic particles were regenerated and stored in the fridge for next 
immunomagnetic separations.  
A schematic illustration for separating antigens from antibody-antigen complexes is 
shown in Fig. 3.10. 
 
Figure 3.10 : Scheme for separation of antigens from antibody-antigen  
 complexes (adapted from K. Syslová et al.) [2]. 
The summary of the principle of the immunomagnetic separation method applied in 
this study can be seen in Fig. 3.11. 
 74 
 
 
Figure 3.11 : Scheme for the principle of the immunomagnetic separation method  
 (adapted from K. Syslová et al.) [2]. 
3.9 LC-ESI-MS/MS Analysis 
In LC-ESI-MS/MS (liquid chromatography combined with electrospray ionization 
tandem mass spectrometry), isocratic mobile phase composition of acetonitrile:water 
(70:30 v/v) was used for the separation of Cys-LTs and 8-iso PGF2α. Flow of the 
mobile phase was 150 µl/min. For the determination of the Cys-LTs and 8-iso PGF2α 
and their deuterium labelled analogues (LTC4-d5, LTD4-d5, LTE4-d5 and 8-iso PGF2α-
d4) by the mass spectrometer, negative electrospray ionization (ESI
-
) in selective 
reaction monitoring (SRM) mode with collision-induced dissociation (CID) was 
used. In particular, the selected reaction monitoring mode was used for its extremely 
high degree of selectivity. Monitoring reactions were: LTC4 624 (precursor ion) → 
271 (product ion) (collision energy: 24 eV), LTD4 495 → 176 (21 eV), LTE4 438 → 
333 (21 eV), and 8-iso Prostaglandin F2α 353 → 193 (27 eV). Conditions on the mass 
spectrometer were optimized to values as follows: spray voltage -2500V (negative 
ion mode), capillary (ion transfer tube) temperature 300°C, HESI vaporizer 
temperature 300°C, sheath gas (nitrogen) pressure 35 psi, auxiliary gas flow 
(nitrogen) 10 ArbU. The data were acquired and processed using the software 
Xcalibur 2.1.0 (Thermo Scientific, USA). 
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3.10 Collection of Exhaled Breath Condensate   
The commercially available condenser EcoScreen (Jaeger, Germany) was used to 
collect the samples of exhaled breath condensate (EBC). All clinical samples were 
collected between 8-12 a.m. The subjects (patients diagnosed with sub-types of 
bronchial asthma and the control group of healthy non-smokers) were encouraged to 
perform a tidal breathing through a mouthpiece connected to the condenser (-20°C) 
for 5-10 minutes (volume of exhaled air was held at a constant level of 120 l) while 
wearing a nose-clip. The acquired volumes of EBC samples ranged between 1-2 ml. 
The EBC sample (1.0 ml) was immediately spiked with 250 pg of each deuterium 
labelled internal standard (LTC4-d5, LTD4-d5, LTE4-d5 and 8-iso PGF2α-d4) and 
consecutively frozen to -80°C. The storage period was not exceeded one month. 
3.11 Preparation of Samples for LC-ESI-MS/MS Analysis – Separation of 
Substances from Exhaled Breath Condensate 
Anti-Cys-LTs/Anti-8-iso PGF2α coated magnetic Fe3O4–chitosan nanoparticles 
(approx. 1 mg) stored in Buffer A with sodium azide were washed two times with 
Buffer B (400 l) and re-suspended in 1 ml EBC. The suspension was incubated 
under shaking for 1 h and supernatant was removed. The nanoparticles were washed 
five times in Buffer B (400 l). The supernatant was removed and the nanoparticles 
were treated with 50 l of glycine solution for 1 min, which caused elution of Cys-
LTs/8-iso PGF2α from the antibody-antigen complex on the surface of the magnetic 
nanoparticles. The resulting supernatant was collected immediately and the sample 
prepared in this way was analyzed by HPLC-ESI-MS/MS. The nanoparticles were 
washed five times in Buffer B (400 l) and the regenerated immunomagnetic 
nanoparticles were stored at 4°C in Buffer A (400 l) with 0.1 % sodium azide (w/v) 
for next immunomagnetic separations. 
3.12 Validation of the Method 
3.12.1 Standard preparation and calibration procedure 
The Cys-LTs and 8-iso PGF2α stock solutions (20 ng/ml) were prepared by diluting 
biomarker standards in the mobile phase (acetonitrile:water). It was used for the 
preparation of a series of calibration samples with following concentrations: 5, 10, 
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25, 50, 100, 250 and 500 pg/50 l water (each calibration sample was spiked with 
250 pg of each internal standards (LTC4-d5, LTD4-d5, LTE4-d5 and 8-iso PGF2α-d4)). 
The peak area of a particular substance with the assigned internal standard was used 
as the function to quantify the concentration. 
3.12.2 Accuracy and precision 
The “EBC blank matrix” was prepared by combining EBC samples from healthy 
subjects and immunomagnetic separation of Cys-LTs and 8-iso PGF2α was repeated 
up to the time where the amount of each particular substance was below limit of 
detection (= LOD; determined by LC-ESI-MS/MS). The aliquot (1 ml) of the “EBC 
blank matrix” was spiked with four different amounts of individual Cys-LTs and 8-
iso PGF2α (25, 50, 100 and 250 pg). Each sample was prepared repeatedly (n = 5). 
These samples were pre-treated by the immunomagnetic separation procedure and 
quantified by LC-ESI-MS/MS. The limits of detection (LOD) and quantification 
(LOQ) were determined using the assay of the “EBC blank matrix” (n = 5). The 
values of LOD and LOQ were calculated as the mean value of the “EBC blank 
matrix” treble signals, three times the amount of the standard deviation for LOD and 
ten times the amount of the standard deviation for LOQ, respectively. Subsequently, 
the mean of each set of concentrations, the standard deviation (SD) and the relative 
standard deviation (RSD) were calculated and the value of the precision parameter 
was determined. The accuracy of the method was calculated as the difference 
between the standards (corresponding concentration level of a particular substrate 
was dissolved in mobile phase and analyzed by LC-ESI-MS/MS) and the samples 
worked out by the pre-treatment procedure. The relative error (RE) and the recovery 
were calculated on this basis. 
3.13 Clinical Study 
The objective of the clinical study was to verify the possibility of using 
immunomagnetic separation procedure as a pre-treatment method in combination 
with LC-ESI-MS/MS for the evaluation of clinical samples. Exhaled breath 
condensate (EBC) samples were collected from persons with two sub-types of 
bronchial asthma (occupational asthma (30 subjects) and hard-to-treat asthma (32 
subjects)). The control group for occupational asthma was represented by 20 healthy 
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subjects with identical average age (45-54 years) and gender (male). The control 
group for hard-to-treat asthma was also represented by 20 subjects with identical 
average age (20-25 years) and gender (male) without bronchial asthma diagnosis 
(healthy subjects). The samples collected during the clinical study were worked out 
by the above-mentioned immunomagnetic separation method and the concentration 
levels of Cys-LTs and 8-iso PGF2α were determined by LC-ESI-MS/MS. 
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4. RESULTS AND DISCUSSION 
4.1 Preparation of Immunomagnetic Nanoparticles 
The magnetic Fe3O4 nanoparticles were firstly synthesized by co-precipitation 
method and oleic acid was used for stabilization. Oleic acid was chemically adsorbed 
onto the surface of the nanoparticles. Then chitosan was added to coat on the surface 
of the Fe3O4 nanoparticles as a polymeric shell. The magnetic Fe3O4–chitosan 
nanoparticles were functionalized by cross-linking the amino groups on the chitosan 
using glutaraldehyde. X-ray diffraction pattern indicated that the magnetic 
nanoparticles were pure Fe3O4 with an average diameter of about 5.7 nm. 
Transmission electron microscopy showed that the magnetic Fe3O4–chitosan 
nanoparticles were quasi-spherical with a mean diameter of about 8.4 nm. The 
binding of chitosan and glutaraldehyde onto the surface of the magnetic Fe3O4 
nanoparticles was also demonstrated by the measurement of Fourier transform 
infrared spectra.  
After these procedures, antibody conjugated magnetic Fe3O4–chitosan nanoparticles 
(immunomagnetic nanoparticles) were prepared. TEM images demonstrated that the 
magnetic Fe3O4–chitosan nanoparticles were anchored with antibodies. These 
immunomagnetic nanoparticles were used to form antibody-antigen complexes on 
them and separate biomarkers from biological complexes like EBC.  
In this study, cysteinyl leukotrienes (Cys-LTs) and 8-iso Prostaglandin F2α (8-iso 
PGF2α) were treated like antigens and they were uncoupled from the formed 
complexes by glycine solution through magnetic separation. The resulting samples of 
these molecules were measured by liquid chromatography combined with mass 
spectrometry. The mass spectrometry results showed that the measured samples 
contained Cys-LTs and 8-iso PGF2α, proving that the isolation of these molecules 
from the complexes, and thus from the immunomagnetic nanoparticles was 
successful and the prepared immunomagnetic nanoparticles actually worked. The 
whole process applied in this study is summarized in Fig. 4.1. 
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Figure 4.1 : Summary of the whole process applied in the study. 
4.2 Characterization of Magnetic Nanoparticles 
4.2.1 Fourier transform infrared spectroscopy (FT-IR) 
For the measurement of infrared spectra, the sample of particles was dispersed in 
acetone and spreaded on a crystal. The solvent evaporated very quickly and the 
spectrum was measured for determination of the presence of oleic acid, chitosan and 
glutaraldehyde on the surface of the magnetic nanoparticles.  
Fourier transform infrared measurements were carried out on the pure oleic acid, 
chitosan, glutaraldehyde solution, magnetic Fe3O4 nanoparticles stabilized with oleic 
acid and magnetic Fe3O4 nanoparticles functionalized with chitosan and 
glutaraldehyde. The spectra can be seen in Fig. 4.2–6. Under the Fig. 4.2, 4.3 and 4.4 
there are tables (4.1, 4.2 and 4.3) with absorption bands identifying the substances. 
 
Preparation of magnetic Fe3O4 nanoparticles
with oleic acid
Functionalization of Fe3O4 nanoparticles 
with chitosan and glutaraldehyde
Anchoring antibodies onto the surface of magnetic 
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Figure 4.2 : The infrared spectrum of pure oleic acid. 
Table 4.1 : Identification of the functional groups of oleic acid
2
. 
Wave number 
[cm
-1
], intensity 
Present band Assignment Functional group 
3050-2995; m 3006 ν (CH) =CH- 
1685-1620; w-m 1648 ν (C=C) >C=C<, >C=CH2 
1415-1340; w 1340 δ (CH) -CH=CH-, cis 
730-665; m 677 γ (CH) R-CH=CH-R', cis 
2955-2915; m 2922 νas (CH2) -(C)-CH2-, -(O)-CH2 
2880-2830; m 2853 νs (CH2) -(C)-CH2-, -(O)-CH2 
1470-1440; m 1458 δ (CH2) -(C)-CH2-, -(O)-CH2 
735-720; w-m 722 ρ (CH2) (CH2)n-(C)-, n>3 
1480-1440; m 1465 δd (CH3) -(C)-CH3, -(O)-CH3 
1395-1345; m-s 1378 δs (CH3) -(C)-CH3, -(O)-CH3 
3300-2500; m, br 
wide bandwidth of 
3300-2500 
ν (OH)+ -COOH 
1725-1700; vs 1707 ν (C=O) -COOH, dimeric form 
1440-1395; w 1433 
δ (OH)+, 
ν (CO) 
-COOH, dimeric form 
1320-1210; m-s 1284 ν (CO) 
-COOH, dimeric form, 
sometimes doublet 
955-915; m, br 935 γ (OH) -COOH, dimeric form 
 
                                                     
2
 Abbreviations used in the tables: w: weak, m: medium, s: strong, vs: very strong, v: variable, br: 
broad; ν: stretching, νas: asymmetric stretching, νs: symmetric stretching, δ: bending, γ: out-of-plane 
bending, δs: in-plane bending (scissoring), ρ: in-plane bending (rocking). 
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Figure 4.3 : The infrared spectrum of chitosan. 
Table 4.2 : Identification of the functional groups of chitosan
3
. 
Wave number 
[cm
-1
], intensity 
Present 
band 
Assignment Functional group 
3450-3300; w-m, br 3351 νas (NH2) -NH2 
3400-3250; w-m, br 3286 νs (NH2) -NH2 
1650-1580; s-m 1647 δ (NH2) -NH2 
1100-1000; w-m   covered ν (CN) R-NH2, often covered by other 
bands 
900- 650; s, br 894 γ (NH) -NH2 
2955-2915; m 2921 νas (CH2) -(C)-CH2-, -(O)-CH2 
2880-2830; m 2871 νs (CH2) -(C)-CH2-, -(O)-CH2 
1470-1440; m 1458 δ (CH2) -(C)-CH2-, -(O)-CH2 
785- 750; w-m covered ρ (CH2) -CH2-CHx, x≠2 
1155-1050; s 1150 νas (COC) -O-, aliphatic ethers 
1140- 900; s   1025 νs (COC) -O-, =C-O-C, aliphatic ethers 
3550-3230; m-s, br Wide 
bandwidth 
of 3500-
2600 
ν (OH) -OH, dimeric and polymeric 
intermol. H-bond 
3200-2500; v, br ν (OH) -OH, intramol. chelating H-
bond 
1440-1310; m-s 1375 δ (COH) tert.-OH, Ar-OH 
1130-1055; s   1059 ν (CO) R2CH-OH, (second.) 
                                                     
3
 Abbreviations as in Table 4.1. 
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Figure 4.4 : The infrared spectrum of 50 % of glutaraldehyde solution. 
Table 4.3 : Identification of the functional groups of glutaraldehyde
4
. 
Wave number 
[cm
-1
], intensity 
Present band Assignment Functional group 
3600-3100; s, br 3336 νas (H2O) H2O in the solvent 
1645-1615; v 1643 δ (H2O) H2O 
2955-2915; m 2954, 2930 νas (CH2) -(C)-CH2-, -(O)-CH2 
2880-2830; m 2875 νs (CH2) -(C)-CH2-, -(O)-CH2 
1470-1440; m 1463, 1444 δ (CH2) -(C)-CH2-, -(O)-CH2 
785- 750; w-m covered ρ (CH2) -CH2-CHx, x≠2 
2755-2650; w 2752 ν (CH)+ -CHO 
1745-1650; vs 1711 ν (C=O) -CHO 
1440-1325; m 1358 δ (CH) -CHO 
975- 780; w 834 γ (CH) -CHO 
 
 
                                                     
4
 Abbreviations as in Table 4.1. 
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Figure 4.5 : The infrared spectrum of oleic acid modified magnetic  
Fe3O4 nanoparticles. 
Fig. 4.5 shows the FT-IR spectrum of the oleic acid modiﬁed Fe3O4 nanoparticles. 
The sharp intense peak at 575 cm
-1
 corresponded to the vibration of the Fe–O bond in 
the crystalline lattice of Fe3O4. This characteristic peak demonstrated that the 
nanoparticles were Fe3O4. The oleic acid molecules in the adsorbed state were 
subjected to the solid surface of Fe3O4 nanoparticles. In the infrared spectrum of the 
pure oleic acid, two sharp bands at 2922 and 2853 cm
-1
 were attributed to the 
asymmetric CH2 stretch and the symmetric CH2 stretch, respectively. In the infrared 
spectrum of Fe3O4 nanoparticles coated with oleic acid, these asymmetric CH2 
stretch and the symmetric CH2 stretch shifted to 2920 and 2851 cm
-1
, respectively. 
The characteristic band at 1709 cm
-1
 was derived from the existence of the stretching 
vibration of C=O of the carboxyl group in oleic acid. A strong absorption band at 
1047 cm
-1
 exhibited the presence of the C–O single bond stretching. At 1550 and 
1593 cm
-1
, two new bands appeared, which were characteristic vibration bands of the 
symmetric νs(-COO-) and asymmetric νas(-COO-) stretches, respectively. These 
results demonstrated that oleic acid was chemically adsorbed onto the surface of 
Fe3O4 nanoparticles. 
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Figure 4.6 : The infrared spectrum of magnetic Fe3O4 nanoparticles stabilized with 
oleic acid and functionalized with chitosan and glutaraldehyde. 
Fig. 4.6 shows the FT-IR spectrum of oleic acid modiﬁed, chitosan and 
glutaraldehyde functionalized Fe3O4 nanoparticles. The peak at 568 cm
−1
 related to 
the Fe–O bond in the Fe3O4 nanoparticles. The infrared bands for the symmetric and 
the asymmetric CH2 stretches in oleic acid could be observed as shifted to 2875 and 
2946 cm
-1
, respectively. The band at 1721 cm
-1
 belonged to the stretching vibration 
of C=O of the carboxyl group in oleic acid. The absorption band at 3427 cm
-1
 
represented the presence of the hydrogen bonded OH group in chitosan. The 
functional group bands between 900-1200 cm
-1
 could be assignable to the vibration 
of C–O–C in chitosan. The peak at 1627 cm−1, which was related to the imine bonds 
(C=N) formed in the cross-linking process, indicated that chitosan reacted with 
glutaraldehyde to form the Schiff base
5
. These results demonstrated that chitosan and 
glutaraldehyde were coated onto the surface of the oleic acid modified magnetic 
Fe3O4 nanoparticles successfully. 
4.2.2 X-ray powder diffraction (XRD) 
The compositions of the sample of the nanoparticles were determined by measuring 
the powder diffraction and comparing the reflextions in diffractogram with the 
library of spectra. Reflextions of the prepared particles corresponded to magnetite 
                                                     
5
 Compounds containing an azomethine group (-C=N-) are known as Schiff bases [163]. 
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with all characteristic peaks of standard Fe3O4. Diffraction maxima (reflextions) of 
magnetite for Co anode were 2θ = 21.3°, 35.1°, 41.5°, 50.6°, 63.3°, 67.4° and 74.4°. 
They could be marked by Miller indexes as (111), (220), (311), (400), (422), (511) 
and (440), respectively. Besides, the evaluating program was able to calculate the 
size of the particles which were in crystalline form. The mean size of the Fe3O4 
nanoparticles was determined to be about 5.7 nm. This was the size of the magnetic 
core in diameter, the shell formed by oleic acid cannot be determined by XRD. The 
calculation of size was not affected by agglomeration of the particles. All significant 
reflections for magnetite can be seen in Fig. 4.7. 
 
Figure 4.7 : Diffractogram of magnetic Fe3O4 nanoparticles. 
4.2.3 Transmission electron microscopy (TEM) 
For the preparation of the sample of the magnetic nanoparticles or immunomagnetic 
nanoparticles for TEM, first glow discharge-activated carbon-coated grids were  
prepared. To make the surface more accessible to water, the carbon grid needs to be 
made hydrophilic. Hence, Polaron sputter-coater modified for activation of carbon 
support films for electron microscopy by glow discharge [164] was used and the 
surface of the grid was made hydrophilic. Then a small drop of the sample of the 
nanoparticles (~5 μL) was placed on this hydrophilic grid and the particles were let 
adsorbing for 60 s. The grid needs to be stained if the sample on it contains organic 
material as proteins. For normal electron microscope viewing, samples are stained 
with a heavy metal salt (uranyl acetate or ammonium molybdate; staining with these 
heavy atoms is called "negative staining") that readily absorbs electrons. For that 
purpose, the samples of the magnetic nanoparticles was negatively stained with 1 % 
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ammonium molybdate and 0.1 % of trehalose in double distilled water on the glow 
discharge-activated carbon-coated grids. After staining, the grids were air-dried on a 
filter paper and the samples prepared in this way were viewed under the electron 
microscope [165]. 
Fig. 4.8–13 show the TEM images for the magnetic Fe3O4–chitosan nanoparticles, 
antibody anchored magnetic Fe3O4–chitosan nanoparticles and antibody anchored 
Dynabeads M-280 Tosylactivated. The images showed that the magnetic Fe3O4–
chitosan nanoparticles were quasi-spherical with a mean diameter of about 8.4 nm, 
and the size of the Dynabeads M-280 Tosylactivated was about 2.9 μm in diameter. 
 
Figure 4.8 : TEM image of the magnetic Fe3O4–chitosan nanoparticles. 
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Figure 4.9 : TEM image of the magnetic Fe3O4–chitosan nanoparticles  
and their sizes in diameter. 
 
Figure 4.10 : TEM image of the antibody anchored magnetic  
Fe3O4–chitosan nanoparticles. 
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Figure 4.11 : TEM image of the antibody anchored magnetic Fe3O4–chitosan 
nanoparticles and their sizes in diameter (The blue color was used 
to show the core sizes and the red was used for showing the  
whole particle size including antibody). 
 
Figure 4.12 : TEM image of the antibody anchored  
Dynabeads M-280 Tosylactivated. 
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Figure 4.13 : TEM image of the antibody anchored Dynabeads M-280 
                                  Tosylactivated and their sizes in diameter. 
4.3 HPLC-ESI-MS/MS Analysis 
Kinetex C18 (2.7 μm) column was used for chromatographic separation of the 
substances. The mobile phase consisted of water and acetonitrile (30:70 v/v) and 
isocratic elution at the flow rate 150 μl/min was used. Mass-spectrometric detection 
was realized using negative electrospray ionization (ESI
–
) in a very selective SRM 
mode. Product spectra for each substance are in Figures 4.14–17. 
 
Figure 4.14 : MS/MS spectrum of LTC4. 
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Figure 4.15 : MS/MS spectrum of LTD4. 
 
Figure 4.16 : MS/MS spectrum of LTE4. 
 
Figure 4.17 : MS/MS spectrum of 8-iso PGF2α. 
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4.4 Calibration Curves and Validation of the Method 
The calibration graphs for Cys-LTs and 8-iso PGF2α were constructed for EBC 
(originally free of Cys-LTs and 8-iso PGF2α). The calibration was created from 
artificially prepared samples with increasing amounts of Cys-LTs and 8-iso PGF2α 
and their corresponding internal standards (250 pg of particular internal standard in 1 
ml EBC) after the pre-treatment by immunomagnetic nanoparticles with anti-LTC4, 
anti-LTD4, anti-LTE4 and anti-8-iso PGF2α antibodies. The samples were 
immediately analyzed by HPLC/MS in MRM mode. Calibration graphs were formed 
using the ratio of a particular biomarker peak area to the corresponding internal 
standard peak area (axis x) versus the biomarker concentration in mobile phase (axis 
y). The calibration curve was evaluated by the least square regression in the form y = 
ax + b. The results are summarized in Table 4.4. All substances exhibited a linear 
dependence within the range starting at the LOQ to 5000 pg with the Pearson‟s 
correlation coefficients (R
2
) higher than 0.992 for all the analytes (the acceptable 
value of R
2
 for each calibration curve was R
2
 ≥ 0.99).  
Table 4.4 : Linear regression analysis of calibration curves  
(n = 10) for Cys-LTs and 8-iso PGF2α. 
Analyte Slope Intercept SD RSD [%] R
2
 
LTC4 59.013 -72.624 1.579 2.676 0.9982 
LTD4 172.440 -250.54 4.289 2.487 0.9926 
LTE4  60.229 -144.87 1.382 2.295 0.9950 
8-iso PGF2α 362.320 -40.81 7.121 1.965 0.9988 
The validation parameters of the method such as the accuracy (RE) and the precision 
(RSD) were assessed by analyzing four various concentration levels of the Cys-LTs 
and 8-iso PGF2α. The LOD and LOQ were estimated by the analysis of the blank 
matrix (n = 5) for each particular biomarker. All the values are summarized in Table 
4.5. 
Table 4.5 : Validation parameters for Cys-LTs and 8-iso PGF2α  
in exhaled breath condensate (n = 5). 
Analyte LOD 
(pg/ml) 
LOQ 
(pg/ml) 
Precision    
RSD (%) 
Accuracy   
RE (%) 
Recovery      
(%) 
LTC4 3 7 8.2 17.8 82.2 
LTD4 2 5 10.4 18.5 81.5 
LTE4  2 4 11.2 17.6 82.4 
8-iso PGF2α 2 6 28.7 19.2 80.8 
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4.5 Repeatability of Immunomagnetic Nanoparticles  
For the repeatability of the magnetic Fe3O4–chitosan nanoparticles with anchored 
antibodies against Cys-LTs or 8-iso PGF2α, it was tried to determine that after one 
performed immunomagnetic separation, if these immunomagnetic nanoparticles 
could be used for further separations of Cys-LTs and 8-iso PGF2α from samples or 
not. 
For that purpose, 5 same samples of Cys-LTs were prepared at concentration of 100 
ng Cys-LTs/100 µl water. The concentration of the stock solution of Cys-LTs was 5 
μg of each leukotriene in 250 μl ethanol. To prepare 100 ng Cys-LTs/100 µl water 
concentration value, 5 μl of the stock solution of Cys-LTs and 95 μl of water were 
put into an Eppendorf tube. The tube was vortexed in the minishaker for 1 min. 5 
samples were prepared in this way. As immunomagnetic nanoparticles, magnetic 
Fe3O4–chitosan nanoparticles with 100 μl of anchored antibodies against Cys-LTs 
were used. They were treated with these prepared Cys-LTs samples, respectively. 
Similarly, 8-iso PGF2α samples were prepared at concentration of 200 ng 8-iso 
PGF2α/100 µl water. The concentration of the stock solution of 8-iso PGF2α was 1 
μg/1 μl. To prepare 200 ng 8-iso PGF2α/100 µl water concentration value, 2 μl of the 
stock solution of 8-iso PGF2α and 998 μl of water were put into an Eppendorf tube. 
The tube was vortexed in the minishaker for 1 min. As immunomagnetic 
nanoparticles, magnetic Fe3O4–chitosan nanoparticles with 50 μl of anchored 
antibodies against 8-iso PGF2α were used. In each five separation process, the 
particles were treated with 100 µl of the prepared 8-iso PGF2α samples, respectively. 
The procedures for formation of antibody-antigen interactions and separation of Cys-
LTs and 8-iso PGF2α from the complexes were followed as described in Section 3.7 
and 3.8. Table 4.6 shows the recovery of Cys-LTs and 8-iso PGF2α in the samples 
measured by LC-MS. 
Table 4.6 : Recovery of Cys-LTs and 8-iso PGF2α in the samples. 
Analyte Recovery (%) 
1 2 3 4 5 
LTC4 99.3  98.7 96.1 94.9 92.0 
LTD4 99.5 99.1 97.2 95.7 94.1 
LTE4 99.1 98.6 96.8 94.2 91.9 
8-iso PGF2α 98.9 98.1 96.9 93.6 90.9 
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As can be seen from the results, after 5 performed separations, the immunomagnetic 
nanoparticles worked without any significant change to bind Cys-LTs or 8-iso PGF2α 
(loss of ability ≤ 10%). So, it was concluded that the magnetic Fe3O4–chitosan 
nanoparticles with anchored antibodies against Cys-LTs/8-iso PGF2α could be used 
for immunomagnetic separations efficiently at least 5 times in a row.  
4.6 Capacity of Immunomagnetic Nanoparticles 
To determine the capacity of anti-Cys-LTs antibody anchored magnetic 
nanoparticles, samples of Cys-LTs were prepared at different concentration values: 
5, 10, 25, 50, 75, 100, 150, 200, 500, 1000, 1500, 2500, 3500, 5500, and 7500 pg 
Cys-LTs each in 100 µl water. As immunomagnetic nanoparticles, magnetic Fe3O4–
chitosan nanoparticles with 100 μl of anchored antibodies against Cys-LTs were 
used. They were treated with these prepared Cys-LTs samples, respectively.  
The procedures for formation of antibody-antigen interactions and separation of Cys-
LTs from the complexes were followed as described in Section 3.7 and 3.8. Fig. 4.18 
shows the capacity of immunomagnetic nanoparticles to isolate LTC4, LTD4, and 
LTE4. 
 
Figure 4.18 : Capacity of immunomagnetic nanoparticles to isolate  
LTC4 ( ), LTD4 ( ) and LTE4 ( ). 
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As can be seen from the Fig. 4.18, at first, as the initial concentration values of Cys-
LTs (LTC4, LTD4, and LTE4) in the samples increased, the amount of Cys-LTs 
separated by the antibodies after the immunomagnetic separations also increased. But 
after a while (after the subsequent separations), the amount of separated Cys-LTs 
became constant showing the maximum binding capacity of the anti-Cys-LTs 
antibodies. After this point, it was pointless to add more Cys-LTs to the samples as 
antigens, because the amount of molecules more than the maximum binding capacity 
of antibodies could not be detected. 
4.7 Mixing of Immunomagnetic Nanoparticles  
One of the main goals of this study was to investigate if the magnetic nanoparticles  
conjugated with different antibodies (anti-Cys-LTs/anti-8-iso PGF2α) could work 
together when they were prepared by different ways. For this purpose, two different 
immunomagnetic separations were carried out. For the first separation process, 
magnetic Fe3O4–chitosan nanoparticles conjugated with 50 μl of antibodies against 
Cys-LTs (MN–Cys-LTs) and magnetic Fe3O4–chitosan nanoparticles conjugated 
with 50 μl of antibodies against 8-iso PGF2α (MN–8-iso PGF2α) were mixed together 
(These immunomagnetic nanoparticles were separately prepared and then mixed 
together).  
For the second separation process, 50 μl of antibodies against Cys-LTs and 50 μl of 
antibodies against 8-iso PGF2α were added to the same magnetic Fe3O4–chitosan 
nanoparticles at the same time (Cys-LTs–MN–8-iso PGF2α) (Section 3.5). 
For both of the immunomagnetic separations, same samples containing both Cys-LTs 
and 8-iso PGF2α were prepared at concentration of 100 ng/100 μl water. The first 
sample was added to the first immunomagnetic nanoparticles ((MN–Cys-
LTs)+(MN–8-iso PGF2α)) and the second sample was added to the second 
immunomagnetic nanoparticles (Cys-LTs–MN–8-iso PGF2α). The procedures for 
formation of antibody-antigen complexes and separation of Cys-LTs and 8-iso PGF2α 
from these complexes were followed as described in Section 3.7 and 3.8. Table 4.7 
shows the recovery of Cys-LTs and 8-iso PGF2α performed by the immunomagnetic 
nanoparticles prepared by two different ways. 
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Table 4.7 : Recovery of Cys-LTs and 8-iso PGF2α in the samples performed by the 
        immunomagnetic nanoparticles prepared by two different ways.  
(MN–Cys-LTs)+(MN–8-iso PGF2α) (Cys-LTs–MN–8-iso PGF2α) 
∑Cys-LTs 8-iso PGF2α ∑Cys-LTs 8-iso PGF2α 
97.3 % 85.1 % 21.3 % 15.4 % 
As the results also indicate that the immunomagnetic nanoparticles prepared for the 
first separation process ((MN–Cys-LTs)+(MN–8-iso PGF2α)) worked better than the 
other immunomagnetic nanoparticles (Cys-LTs–MN–8-iso PGF2α) in separating Cys-
LTs and 8-iso PGF2α from the samples. The reason might be either the antibodies on 
the Cys-LTs–MN–8-iso PGF2α couldn‟t be immobilized on the surface of the 
nanoparticles, or they did, but this time the orientation of them were not good enough 
for binding Cys-LTs and 8-iso PGF2α. Another reason might arise from the surface 
competition between the different antibodies (anti-Cys-LTs and anti-8-iso PGF2α) for 
the same binding sites on the nanoparticles. 
4.8 Dynabeads M-280 Tosylactivated with Anchored Antibodies Against 
Cysteinyl Leukotrienes  
Antibodies were also conjugated to the Dynabeads M-280 Tosylactivated to compare 
with the immunomagnetic Fe3O4–chitosan nanoparticles. They were prepared with 
100 µl of antibodies against Cys-LTs as described in Section 3.6. The samples to be 
added to these immunomagnetic Dynabeads were prepared at concentration of 100 
ng Cys-LTs/100 µl water. The immunomagnetic Dynabeads were treated with these 
five Cys-LTs samples, respectively. The procedures for formation of antibody-
antigen interactions and separation of Cys-LTs from the complexes were followed as 
described in Section 3.7 and 3.8.  
From the results, it was concluded that 99.8 % of Cys-LTs could be separated by the 
anti-Cys-LTs antibody (100 µl) anchored Dynabeads. Compared to the results of 
magnetic Fe3O4–chitosan nanoparticles with 100 µl of anchored antibodies against 
Cys-LTs, Dynabeads M-280 Tosylactivated with the same amount of anchored 
antibody against Cys-LTs showed similar results.  
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4.9 Clinical Study 
The aim of the clinical study was to evaluate the concentration levels of cysteinyl 
leukotrienes and 8-iso Prostaglandin F2α in exhaled breath condensate (EBC) of 
patients with two types of asthma: occupational asthma and hard-to-treat asthma. The 
concentrations were compared with control groups. The groups of patients differed in 
age; occupational asthma patients were older than hard-to-treat-asthma patients (See 
Section 3.13 in Experimental Part), therefore two different control groups were 
chosen. 
The data were processed statistically (Fig. 4.19–22). A difference between 
concentration levels of each biomarker could be observed. The difference between 
the group of patients with hard-to-treat asthma and the control group was more 
significant than the same for occupational asthma. This could be arised from the 
differences in age of subjects, because the biomarkers are also present in the body of 
healthy people and their concentration increases with ageing. 
 
Figure 4.19 : Concentration of 8-iso Prostaglandin F2α in EBC in clinical study. 
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Figure 4.20 : Concentration of LTC4 in EBC in clinical study. 
 
Figure 4.21 : Concentration of LTD4 in EBC in clinical study. 
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Figure 4.22 : Concentration of LTE4 in EBC in clinical study. 
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5. CONCLUSIONS 
The oleic acid modified magnetic Fe3O4 nanoparticles were synthesized from ferrous 
and ferric iron solutions by co-precipitation method with a mean diameter of about 
5.7 nm. The magnetic nanoparticles were coated and functionalized with chitosan 
and glutaraldehyde. These Fe3O4–chitosan nanoparticles had an average size of 8.4 
nm diameter. Antibodies against cysteinyl leukotrienes and 8-iso Prostaglandin F2α 
were conjugated to these magnetic Fe3O4–chitosan nanoparticles, and the prepared 
immunomagnetic nanoparticles were used to separate biomarkers (Cys-LTs and 8-iso 
PGF2α) from biological matrix of EBC by immunomagnetic separation method. The 
amounts of the separated molecules were determined by a highly selective and 
sensitive detection method: mass spectrometry combined with high-performance 
liquid chromatography (HPLC-MS).  
The results showed that the clinic using of these immunomagnetic nanoparticles for 
separation of biomarkers (LTC4, LTD4, LTE4 and 8-iso PGF2α) in EBC of patients 
with sub-types of bronchial asthma (occupational and hard-to-treat) and healthy 
subjects, where reasonable differences in Cys-LTs and 8-iso PGF2α concentration 
levels were found, was efficient. The performed clinical study confirmed the 
possibility of differential diagnosis of bronchial asthma using the developed pre-
treatment method. The detection of elevated inflammatory and oxidative stress 
mediators (Cys-LTs and 8-iso PGF2α) in EBC of subjects with relatively 
asymptomatic asthma and normal pulmonary function tests could offer a novel way 
for monitoring the lung inflammation and perhaps initiating treatment in an earlier 
stage. The simplicity, rapidity, and robustness of the whole method make it suitable 
for use as a high-throughput assay in routine clinical biochemical laboratories. 
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